Panchanan Maiti1,2,3,4,5,6, Jason Scott7, Dipanwita Sengupta8, Abeer Al-Gharaibeh9,10, Gary L Dunbar11,12,13,14. 1. Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA. maiti1p@cmich.edu. 2. Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA. maiti1p@cmich.edu. 3. Department of Psychology, Central Michigan University, Mt. Pleasant, MI 48859, USA. maiti1p@cmich.edu. 4. Field Neurosciences Institute, St. Mary's of Michigan, Saginaw, MI 48604, USA. maiti1p@cmich.edu. 5. Department of Biology, Saginaw Valley State University, Saginaw, MI 48710, USA. maiti1p@cmich.edu. 6. Brain Research Laboratory, Saginaw Valley State University, Saginaw, MI 48710, USA. maiti1p@cmich.edu. 7. Department of Biology, Saginaw Valley State University, Saginaw, MI 48710, USA. jascott1@svsu.edu. 8. Field Neurosciences Institute, St. Mary's of Michigan, Saginaw, MI 48604, USA. Dipanwita.Sengupta@ascension.org. 9. Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA. to.abeer@gmail.com. 10. Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA. to.abeer@gmail.com. 11. Field Neurosciences Institute Laboratory for Restorative Neurology, Central Michigan University, Mt. Pleasant, MI 48859, USA. dunba1g@cmich.edu. 12. Program in Neuroscience, Central Michigan University, Mt. Pleasant, MI 48859, USA. dunba1g@cmich.edu. 13. Department of Psychology, Central Michigan University, Mt. Pleasant, MI 48859, USA. dunba1g@cmich.edu. 14. Field Neurosciences Institute, St. Mary's of Michigan, Saginaw, MI 48604, USA. dunba1g@cmich.edu.
Abstract
Autophagy and the (PI3K-Akt/mTOR) signaling pathway play significant roles in glioblastoma multiforme (GBM) cell death and survival. Curcumin (Cur) has been reported to prevent several cancers, including GBM. However, the poor solubility and limited bioavailability of natural Cur limits its application in preventing GBM growth. Previously, we have shown the greater apoptotic and anti-carcinogenic effects of solid lipid Cur particles (SLCP) than natural Cur in cultured GBM cells. Here, we compared the autophagic responses on cultured U-87MG, GL261, F98, C6-glioma, and N2a cells after treatment with Cur or SLCP (25 µM for 24 h). Different autophagy, mitophagy, and chaperone-mediated autophagy (CMA) markers, along with the PI3K-AKkt/mTOR signaling pathway, and the number of autophagy vacuoles were investigated after treatment with Cur and or SLCP. We observed increased levels of autophagy and decreased levels of mitophagy markers, along with inhibition of the PI3K-Akt/mTOR pathway after treatments with Cur or SLCP. Cell survival markers were downregulated, and cell death markers were upregulated after these treatments. We found greater effects in the case of SCLP-treated cells in comparison to Cur. Given that fewer effects were observed on C-6 glioma and N2a cells. Our results suggest that SLCP could be a safe and effective means of therapeutically modulating autophagy in GBM cells.
Autophagy and the (PI3K-Akt/mTOR) signaling pathway play significant roles in glioblastoma multiforme (GBM) cell death and survival. Curcumin (Cur) has been reported to prevent several cancers, including GBM. However, the poor solubility and limited bioavailability of natural Cur limits its application in preventing GBM growth. Previously, we have shown the greater apoptotic and anti-carcinogenic effects of solid lipid Cur particles (SLCP) than natural Cur in cultured GBM cells. Here, we compared the autophagic responses on cultured U-87MG, GL261, F98, C6-glioma, and N2a cells after treatment with Cur or SLCP (25 µM for 24 h). Different autophagy, mitophagy, and chaperone-mediated autophagy (CMA) markers, along with the PI3K-AKkt/mTOR signaling pathway, and the number of autophagy vacuoles were investigated after treatment with Cur and or SLCP. We observed increased levels of autophagy and decreased levels of mitophagy markers, along with inhibition of the PI3K-Akt/mTOR pathway after treatments with Cur or SLCP. Cell survival markers were downregulated, and cell death markers were upregulated after these treatments. We found greater effects in the case of SCLP-treated cells in comparison to Cur. Given that fewer effects were observed on C-6 glioma and N2a cells. Our results suggest that SLCP could be a safe and effective means of therapeutically modulating autophagy in GBM cells.
According to the World Health Organization (WHO), glioblastoma multiforme (GBM) is one of the deadliest and most aggressive brain cancers, affecting millions of people world-wide. Histopathological analysis revealed that brain tumors account for 85% to 90% of all primary Central nervous system (CNS) tumors, and about 70% to 80% are of glial cell origins. Whereas among all primary brain tumors only 15% are GBM [1]. Importantly, most GBM patients survive on average for only 15 to 20 months following initial diagnosis [2]. Despite current neurosurgical, radiotherapy, and chemotherapeutic advancement, the GBM growth and proliferation cannot be effectively controlled. The most potent chemotherapeutic drug use to treat GBM is temozolomide (Temodar, TMZ), but resistance to TMZ limits its effectiveness. Moreover, neuroinflammation also increases after treatment of TMZ, making the development of alternative therapies critically important. In this context, several investigators have studied the anti-cancer and anti-inflammatory effects of curcumin (Cur) in humanmalignancies, including those found in various tissues, such as breast, prostate, colon, liver, and brain [3,4].Several anti-cancer drugs have been tested to prevent GBM cell growth and metastasis [4]. Many of these drugs kill GBM cells by inducing apoptosis, autophagic cell death, or necrosis, whereas dysregulation of these major pathways promotes cancer development [5]. Although apoptosis is the most common form of programmed cell death (PCD), autophagic cell death also has significant roles in tumorigenesis [5]. It includes macroautophagy, microautophagy, and chaperones-mediated autophagy (CMA), which are highly conserved cellular-debris disposal mechanisms by which cellular organelles, misfolded protein aggregates, and pathogens or toxins are degraded through fusion of the resulting autophagosomes with lysosomes [6,7,8]. The beneficial effects of autophagy have been observed with anti-cancer drugs after their treatments in GBM cells, which may either induce or bypass the apoptotic pathway, depending on cellular stress [9]. Several experimental results from animal studies and cell culture studies have demonstrated that induction of autophagy or type-II PCD can induce or inhibit type-I PCD or apoptosis [10], which suggests that they are inter-linked for cell death and survival [11]. In addition, cancer cell growth and proliferation are also controlled by the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR, also known as the mechanistic target of rapamycin and FK506-binding protein 12-rapamycin-associated protein 1) sensitive mTOR-complex (PI3K-Akt/mTOR) pathway, which has inhibitory roles on the autophagic pathway. The Akt/mTOR pathway plays significant roles in the regulation of autophagy, as well as cancer cell growth and proliferation; inhibition of this pathway has activatory roles in the autophagy pathway and inhibitory roles on cancer cell proliferation. Therefore, targeting autophagy by inhibiting PI3K-Akt/mTOR might be a potent strategy to inhibit GBM growth and proliferation [12].Curcumin (Cur), is the most active natural polyphenol present in the turmeric root of the herb, Curcuma longa [13]. For a long time, it has been known to function as a potent inhibitor of tumor growth, proliferation, invasion, angiogenesis, and metastasis. Cur has been applied for several cancer therapies, including GBM [14]. It can attenuate cancer growth by increasing oxidative stress, disrupting PI3k-Akt/mTOR signaling and induction of apoptosis, but it requires higher amounts to be effective against cancer cells [15]. Unfortunately, poor solubility and instability in physiological fluids limits its therapeutic application for targeting GBM [16,17]. Although various lipidated and nanotechnological approaches of Cur formulations have been shown to increase its solubility and bio-availability [15], none of these produce optimal levels. Recently, solid lipid particles (SLPs), conjugated with Cur (SLCPs), have been characterized by our laboratory [15,18,19] and those of others to increase Cur solubility, stability, and bioavailability [20,21,22,23,24,25], when tested in an in vitro model of GBM, as well as animal models and clinical trials of Alzheimer’s disease [26,27].Previously, we have reported that SLCPs induce a greater number of apoptotic deaths than natural Cur in U-87MG [19]. In the present study, we have designed the experiments to compare the autophagy mechanism, including mitophagy and the PI3K-Akt/mTOR pathway (which is one of the modulators of the autophagy pathway) in vitro, using GBM cells derived from human (U-87MG), mouse (GL261), and rat (F98) origins, their respective rat glial tumor cells (C6-glioma), and mouseneuroblastoma cells (N2a cells) after treatment with Cur and/or SLCP. Our results suggest that SLCP induced autophagy markers greater than natural Cur, as well as the inhibition of mitophagy and the significant disruption of the PI3K-Akt/mTOR pathway in all three GBM cells, without significant effects on C6-glioma and N2a cells.
2. Results
In this study, we have compared the levels of autophagy, including mitophagy markers and the PI3k-Akt/mTOR signaling pathway in cultured GBM cells after treatment with SLCP and or Cur.
2.1. SLCP Induced Autophagy Greater than Natural Cur in Different GBM Cells
We have investigated different autophagy markers, such as Atg5, Atg7, Beclin-1, LC3A/B, and p62, from all three GBM cell lines (U-87MG, GL261, and F98), and from C6-glioma and N2a cells. We observed that the Atg5 level was significantly increased (p < 0.05) in U-87MG and F98 cells, but not in GL261 after treatment with Cur and or SLCP in comparison to vehicle-treated groups (Figure 1A,B). Similarly, we found a significant increase (p < 0.01) in levels of Atg7 after Cur and or SLCP treatment in U-87MG and GL261, but not in F98 cells, in comparison to the vehicle-treated group (Figure 2A,C). Furthermore, the Beclin-1 level was also significantly increased (p < 0.05) in all three GBM cells after treatment with Cur or SLCP in comparison to the vehicle group (Figure 1A,D). We also observed that the ratio of LC3A/B-II/LC3A/B-I was significantly increased by Cur and or SLCP treatment in all three GBM cells lines in comparison to vehicle-treated cells (Figure 1A,D). SLCP-treated cells had more changes in autophagic markers, overall, than did Cur-treated cells. Similar to the Western blot data, the immunofluorescence intensity of Atg5, Atg7, Beclin-1, and LC3A/B all tended to increase in U-87MG cells after treatment with Cur and or SLCP, in comparison to vehicle-treated cells (Figure 1G).
Figure 1
Changes of autophagy markers in GBM cells after treatment with Cur and or SLCP. (A–F): U-87MG, GL261, and F98 cells were treated with either Cur or SLCP (25 µM) for 24-h and then Western blots and immunocytochemistry (ICC) were performed. The Western blots data showed that there were significant increased levels of Atg5, Atg7, Beclin-1, LC3A/B, and p62 after treatment with SLCP and/or Cur. Values are represented as mean ± standard error of mean (SEM) from three independent observations. * p < 0.05 in comparison to the respective vehicle-treated group. (G): Immunocytochemisty (ICC) revealed apparent increases in ICC intensity of Atg5, Atg7, Beclin-1, and LC3/A/B in SLCP- and Cur-treated U-87MG cells in comparison to vehicle-treated cells. Scale bar indicates 50 µm and is applicable to all images.
Figure 2
Changes of autophagy markers in C6-glioma and N2a cells after treatment with SLCP and Cur. C6-glima and N2a cells were treated with either Cur or SLCP (25 µM) for 24-h prior to performing Western blots and ICC. (A–E): The Western blots analyses revealed that there were no significant changes of autophagy markers following treatment, except Atg7 levels were significantly decreased in both cell lines (C) and Beclin-1 levels were increased in C6-glioma (D). Values are represented as mean ± SEM from three independent observations. * p < 0.05 in comparison to the respective vehicle-treated cells. (F): ICC of autophagy markers in N2a cells showed that there were no major changes of the immunofluorescent signal for these parameters. Scale bar indicates 50 µm and is applicable to all images.
2.2. Cur and or SLCP Treatment Has Little Influence on Autophagy Pathways in Rat Glial Tumor Cells (C6-Glioma) and Mouse Neuroblatsoma (N2a) Cells
We did not observe any significant changes of Atg5 (Figure 2A,B) and LC3A/B levels (Figure 2A,E) after treatment with Cur and or SLCP treatment. In addition, we observed very little differences of Atg7 levels in C6-glioma cells, and there was a decrease in N2a cells (Figure 2A,C) after Cur and or SLCP treatment. In contrast, Beclin-1 was increased in C6-glioma, but not in N2a cells (Figure 2A,D) after Cur and or SCLP treatment. The ICC of Atg5, Atg7, Beclin-1, and LC3A/B in U-87MG also showed comparable results, as shown in the Western blots after Cur and/or SLCP treatment (Figure 2F).
2.3. SLCP Inhibits Mitophagy Markers More than Cur in GBM Cells.
We also investigated the most important mitophagy markers, such as BNIP3L/NIX, FUNDC1, BNIP3, PINK-1, and HIF-1α, by Western blots. We observed that BNIP3L/NIX was significantly decreased in GL261 and F98 cells (p < 0.05) and there was a trend of reduction of this protein in U-87MG after treatment with Cur and SLCP, in comparison to the vehicle-treated group (Figure 3A,B). Similarly, the FUNDC1 level was also significantly decreased in SLCP-treated cells greater than the Cur treated and vehicle-treated group (Figure 3A,C). In addition, BNIP3, PINK-1, and HIF-1α levels were also significantly decreased (p <0.05) in Cur and or SLCP-treated cells in comparison to the vehicle-treated group (Figure 3A,D,E). Whereas, we found a significant decrease of BNIP3L/NIX and HIF-1α in C6-glioma and N2a cells after treatment with Cur and or SLCP (Figure 3F–I), whereas no significant changes were observed in the case of FUNDC1 protein in both the cell lines (Figure 3F,H).
Figure 3
Mitophagy markers were down-regulated more in GBM cells by SLCP than by Cur. U-87MG, GL261, F98, C6-glioma, and N2a cells were treated with either Cur or SLCP (25 µM for 24-h) prior to Western blots analyses. The levels of BNIP3L/NIX, FUNDC1, BNIP3, PINK-1, and HIF-1α were significantly down-regulated (p < 0.05) after treatment of SLCP and or Cur in all three GBM cell lines (A–E), and SLCP showed greater decreases of these parameters than did Cur. Both NIX and HIF-1α were decreased in C6-glioma and N2a cells, but not FUNDC1 (F–I). Values are represented as mean ± SEM from three independent observations. * p < 0.05 and ** p < 0.01, in comparison to the respective vehicle-treated cells.
2.4. SLCP Inhibits PI3K-Akt/mTOR Pathway Activity in GBM Cells More than Cur does in GBM
We observed that PI3Kp85, phosphoPI3Kp85, total Akt, p-AKT, mTOR, and p-mTOR levels were significantly decreased in U-87MG, GL261, and F98 cell lines after treatment with Cur and or SLCP (Figure 4A–D). SLCP showed greater inhibition of the PI3k-Akt/mTOR pathway than Cur. Whereas in the case of C6-glioma and N2a cells, this pathway was mostly unaltered (Figure 4G–K).
Figure 4
SLCP inhibited the PI3K-Akt/mTOR pathway greater than Cur in cultured GBM cells. U-87MG, GL261, F98, C6-glioma, and N2a cells were treated with either Cur or SLCP (25 µM for 24-h) prior to Western blots and ICC. (A–G): Western blots analyses revealed that PI3Kp85, pPI3Kp85, total Akt, p-Akt (Ser473), mTOR, and p-mTOR levels were significantly decreased in all three GBM cells after treatment with Cur and or SLCP, in comparison to the respective vehicle-treated cells. These parameters were unaltered in C6-glioma and or N2a cells (H–L), except that pAkt was significantly increased in C6-glioma after the treatment. Values are represented as mean ± SEM from three independent observations. * p < 0.05 and ** p < 0.01 in comparison to their respective vehicle-treated cells.
2.5. Cur and or SLCP Treatment Inhibited Chaperone-Mediated Autophagy (CMA) Markers in GBM Cells.
CMA markers, such as HSC70, were unaltered in all three GBM cell lines, but LAMP2A levels were significantly down-regulated after treatment with Cur and or SLCP (Figure 5A,D,E). In contrast, HSP70 was increased in all three cell lines after treatment with Cur and or SLCP (Figure 5A,B), and the HSP90 level was also diminished in U-87MG and GL261, but was increased in F98 cells treated with SLCP (Figure 5A,C).
Figure 5
Chaperone-mediated autophagy markers were inhibited in GBM cells after SLCP or Cur treatment. U-87MG, GL261, F98, C6-glioma, and N2a cells were treated with either Cur or SLCP (25 μM for 24-h) prior to Western blots. HSC70 levels were unaltered by SLCP or Cur treatment, while LAMP2A levels were significantly decreased in all the GBM cell lines (A,D,E). There were significant increases in levels of HSP70 (A,B) and significant decreases in levels of HSP90 (A,C, but in F98 by SLCP) after treatment with Cur or SLCP treatments. The changes were more in the case of SLCP-treated cells in comparison to Cur-treated cells. Values are represented as mean ± SEM from two independent observations. * p < 0.05 and ** p < 0.01, in comparison to their respective vehicle-treated group.
2.6. Cell Survival and Cell Death Markers Were also Modulated by SLCP More than Cur in GBM Cells.
There was a significant increase (p < 0.01) in Bax and Cyt-c and caspase-3 levels in both Cur and SLCP-treated cells in comparison to vehicle-treated cells (Figure 6A–E). In contrast, there was a significant decrease of Bcl-2 in GL261 and F98 cells (Figure 6A,B). Unlike GBM cell lines, Bax and Bcl2 were unaltered in C6-glioma and N2a cells (Figure 6F,G), but Cas-3 (Figure 6F,J) levels were increased in C6-glioma, while being unaltered in N2a cells after Cur or SLCP treatment, in comparison to vehicle-treated cells.
Figure 6
Cell death and cell survival markers in GBM cells. U-87MG, GL261, F98, C6-glioma, and N2a cells were treated with either Cur or SLCP (25 µM for 24-h) prior to Western blots analyses. Western blots analyses showed that SLCP and Cur treatments increased Bax, Cyt-c, and caspase-3 and decreased Bcl2 in all three GBM cell lines, in comparison to vehicle-treated cells (A–E). Cell survival and cell death markers were unaltered in the case of C6-glioma and N2a cells, except for Caspase-3, which was increased in C6-glioma after both of these treatments. Values are represented as mean ± SEM from two independent observations. * p < 0.05 and ** p < 0.01 in comparison to either in Cur-treated or to vehicle-treated cells.
2.7. SLCP Treatment Produced Greater Increases in the Number of Autophagy Vacuoles in U-87MG Cells than Did Cur Treatments
To investigate the degree of formation of autophagy vacuoles (AV) after Cur or SLCP-treatment, U-87MG cells were treated with SLCP and/or Cur for 24 h. TEM images indicated that there were significantly more autophagy vacuoles in SLCP-treated cells (p < 0.01) in comparison to Cur-treated cells (Cur: 61.00% and in SLCP: 163.84%) (Figure 7A,B). In addition, SLCP treatments increased membrane blebbing, cytoskeleton disorientation, and chromosomal condensation more in U-87MG cells than Cur-treated cells (Figure S1).
Figure 7
SLCP treatments resulted in more autophagy vacuole formations in U-87MG cells than did treatments with Cur. U-87MG cells were grown and treated with either Cur or SLCP (25 µM for 24-h). Cells were processed for TEM and images were taken with JEOL-TEM. (A): Representative TEM images showing that the numbers of autophagy vacuoles were significantly increased (B) in the case of SLCP-treated cells compared to Cur-treated cells. (C): Fusion of two autophagy vacuoles (red arrow), autophagolysosome complex (black arrow), and mitophagy (white arrow) after treatments with SLCP for 24 h. Scale bars indicate 1 µm. V-vacuole, AV-autophagy vacuoles, arrow indicates autophagy vacuoles. * p < 0.05 and ** p < 0.01 compared to vehicle group; ## p < 0.01 compared to Cur-treated cells.
3. Discussion
Accumulated experimental evidence supports the contention that the dysregulation of autophagy mechanisms significantly contributes to GBM cell death and survival [10]. In the present study, we compared the role of natural Cur or SLCP (a greater permeable solid lipid Cur formulation) on autophagy markers, including mitophagy and chaperone-mediated autophagy pathways in cultured GBM cells. We found a greater induction of autophagy markers, including an increased number of autophagy vacuoles, along with a significant decrease in the levels of mitophagy markers and inhibition of the PI3K-Akt/mTOR pathway by SLCP than by natural Cur in different GBM cell lines, without significantly affecting the rat glial tumor cells (C6-glioma) and mouseneuroblastoma (N2a) cells.Given the present lack of effectiveness and the preponderance of side-effects when the current standard chemotherapies for GBM are used [28,29], many laboratories, including our own, have started investigating natural anti-cancer agents, such as Cur [2,30]. However, to avoid the poor solubility, rapid degradation, and limited bio-availability of natural Cur [17,23], we utilized more permeable solid lipid Cur particles (SLCP) [15,18,19]. Previously, we have demonstrated that SLCP has greater anti-cancer effects in U-87MG cells than does natural Cur [19]. However, its role in autophagy mechanisms in GBM cells remained unexplored. Given that Cur has been shown to induce autophagy, we hypothesized that using SLCP, with its higher solubility and greater membrane permeability, would have stronger modulatory effects on autophagy than natural Cur. Therefore, we investigated different autophagy markers in three different GBM cells (U-87MG, GL261, and F98) after treatment with Cur and or SLCP.GBM cell metastasis can be prevented by induction of apoptosis [31]. However, cells can die by alternative pathways, such as autophagy. Interestingly, when autophagy is induced, either at earlier or later stages, it may lead to non-apoptotic cell death [32]. In addition, cells with a dysfunctional apoptotic pathway may undergo autophagic cell death [33]. Thus, the timing and magnitude of the cellular stresses seem to dictate whether autophagy or apoptosis will be activated. Moreover, autophagy preceded apoptosis, and this mechanism makes the cells more susceptible to death [10]. Given this, we sought to understand the mechanisms of autophagy, including mitochondrial autophagy (mitophagy) and CMA markers, in cultured GBM cells by comparing the treatment effects of SLCP with those of natural Cur.To monitor the autophagy mechanism in GBM cells after treatment with Cur or SLCP, we investigated the Atg5, Atg7, Beclin-1 and LC3A/B, and p62. Atg5 and Atg7 are considered to be essential molecules for the induction of autophagy [34]. For example, defective Atg5 or Atg7 expression consequences decreased autophagic activity in animals [9]. In the present study, we observed an up-regulation of these two markers in all three GBM cells, (except Atg5 in U-87MG cells) (Figure 1) after treatment with Cur and or SLCP, suggesting the induction of autophagosome formation, which has been verified by transmission electron microscopic studies (Figure 7). Similarly, Beclin-1 is an important autophagosome initiation tumor suppressor protein, whose expression is reduced in many cancers. It interacts with Bcl-2 and can induce apoptosis by activating the function of mitochondrial permeability transition pore (MPTP) [35]. Overexpression of Beclin-1 in U-87MG cells enhances the capacity for cellular autophagy, whereas silencing of Beclin-1 decreases autophagic capacity [36]. We found an increase in beclin-1 levels after Cur and/or SLCP treatment, suggesting an enhancement of the autophagy pathway (Figure 1). Our findings are supported by Liang and colleagues, who also found that over-expression of Beclin-1 in U-87MG cells enhanced the capacity for cellular autophagy and induced apoptosis, whereas silencing of Beclin-1 decreased autophagic capacity [36].LC3A/B is the key structural component of the autophagosome formation [37]. The amount of LC3-II reflects the number of autophagosomes and autophagy-related structures and a decrease of its level indicates an impairment of this process. Therefore, levels of LC3 are considered the most reliable marker to monitor autophagy. We observed an increase in the levels of LC3A/B-II after treatment with Cur or SLCP, indicating autophagosome formation was enhanced, which was supported by the recent in vitro work of Guo and colleagues [38]. Although the amount of LC3-II at a given time point does not necessarily estimate the autophagic activity, because inhibition of autophagosome degradation sometimes increases the amount of LC3-II, most cases reveal that increased amounts of LC3-II reflect the number of autophagosomes, thus increased levels of LC3A/B, suggesting that the autophagy mechanism was induced by these treatments (Figure 1). In addition, we also investigated the levels of sequestosome 1 (SQSTM1) or p62, which binds directly to LC3. Increased levels of LC3A/B-II and p62 indicate an increased accumulation of autophagosome formation, which is correlated with an increase in autophagic vacuoles (AV), as revealed by our TEM studies. Although increased levels of p62 inhibit autophagy mechanisms, and decreased levels can be observed when autophagy is induced, therefore, p62 levels may be used as a marker to study autophagic flux. We found that p62 levels were increased by Cur or SLCP treatment, which may be due to blocking of the fusion of autophagy vacuoles with lysosome or by the inhibition of a later maturation step of autophagosome degradation. The overall accumulated increase in AVs in cells by these treatments could induce autophagy-related cell death. Recently, Zanotto-Filho and colleagues showed that autophagy induction improves the efficacy of Cur and or TMZ combination therapy in animal models of glioblastomas, suggesting Cur is a potent autophagy inducer in GBM cells [39].As GBM cells are resistant to apoptosis, the mammalian target for the rapamycin (mTOR) signaling pathway plays an important role [40]. In fact, the mTOR pathway has emerged as a major effector of cell growth and proliferation and is an attractive target for cancer therapy [41,42]. Indeed, mTOR and phosphorylated mTOR (p-mTOR, active form of mTOR) is a potent blocker of autophagy [43]. Thus, inhibiting the mTOR pathway could be a viable strategy to induce autophagy-related cell death to prevent GBM growth. These proteins are controlled by the cellular PI3K and Akt levels. Increases in PI3K activate Akt, which activates the mTOR pathway and induces tumorigenesis, whereas their inhibition prevents activation of this pathway [44]. We observed a significant decrease in levels of PI3Kp85, phosphorylated PI3Kp85, total Akt, p-Akt, mTOR, and p-mTOR after treatment with Cur and or SLCP, indicating PI3K-Akt/mTOR pathways were significantly affected by these treatments, which corresponds to recent findings of Yu and colleagues [45]. Decreased mTOR levels have been shown to induce autophagy [46]. Interestingly, we observed greater levels of PI3K-Akt/mTOR inhibition in SLCP-treated cells (Figure 4) than in Cur-treated cells, indicating greater induction of autophagy by SLCP than natural Cur, which was further supported by increased levels of autophagy markers and the number of AV (Figure 7). Recently, Guo and colleagues also reported that Cur may protect cells against oxidative stress-induced damage through induction of autophagy via inhibition of the Akt/mTOR pathway [38]. Similarly, using in vitro and in vivo models of GBM, Zhuang and colleagues also reported that Cur promotes differentiation of glioma-initiating cells by inducing autophagy [47]. Furthermore, Aoki and colleagues reported that Cur suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy by inhibition of the Akt/mTOR/p70S6K pathway and activation of the ERK1/2 pathway [48]. The above observations were supported by the work of Zhao and colleagues, who reported that Cur potentiates the anti-tumor activities against GBM by suppressing the PI3K/AKT and NF-κB/COX-2 signaling pathways [14]. All these previous observations further supported and confirmed our findings.In addition, we investigated the mitophagy markers. Mitophagy is a selective form of macroautophagy in which mitochondria are targeted for degradation in autophagolysosomes [49,50]. Although mitophagy is not a mechanism of autophagy, it is a special type of autophagy pathway, but it has beneficial effects, especially for the elimination of old and/or damaged mitochondria, thus maintaining the integrity of the mitochondrial pool. Inhibition of mitophagy has adverse effects on mitochondrial health and cell survival [49]. In addition, mitophagy also plays a key role in reducing mitochondrial mass [49]. We have investigated mitophagy markers, such as BNIP3L/NIX, FUNDC1, BNIP3, PINK-1, and HIF-1α (Figure 3). BNIP3L (Bcl2 and adenovirus E1B 19-kDa-interacting protein 3-like), also known as NIX, are the proteins which interact with Bcl2 and are involved in cell death and autophagy, suggesting that BNIP3L/NIX are implicated in the pathogenesis of cancer [51]. BNIP3L is required for interaction with Bcl2, the main anti-apoptotic protein present in mitochondria, whereas decreased levels of BNIP3L may inhibit interactions with Bcl2, thus indirectly inducing cell death [51]. Similarly, BNIP3 is another mitophagy marker, which has a similar role in mitophagy, like BNIP3L/NIX. We found a greater decrease in levels of both NIX and BNIP3 in the case of SLCP (Figure 3), which suggests that SLCP has greater capability to induce cell death. Moreover, in tumor cells, NIX and BNIP3 regulate mitophagy in response to hypoxia, and the deregulation of NIX and BNIP3 expression is associated with increased tumor growth [51]. One of the factors noted in most malignancies is the hypoxic environment, where hypoxia-inducing factor-1α (HIF-1α) levels increase. This factor is a positive regulator of NIX and BNIP3 expression. Therefore, reduction of HIF-1α may down-regulate NIX or BNIP3 levels. For example, knock-down of HIF-1α in glioma cells significantly impairs their migration in vitro, as well as their ability to invade into the brain parenchyma in vivo [52]. In addition, HIF-1α acts as an activator of angiogenic factors, such as placenta-like growth factor and platelet-derived growth factor. Therefore, decreased levels of HIF-1α may be one of the reasons for the down-regulation of NIX or BNIP3 levels, indicating a reduction of mitophagy and induction of cell death.Like NIX and BNIP3, FUNDC1 is an adaptor molecule present at the outer membrane of mitochondria [53]. NIX, BNIP3, and FUNDC1 interact with Bcl-2 or Bcl-XL and modulate in binding with LC3 and recruit components of the autophagy machinery to the mitochondria. Therefore, inhibition of these adaptor proteins, along with decreased HIF-1α after treatment with Cur and or SLCP, indicates decreased mitophagy, which may lead to induction of cell death [49]. Greater inhibition of these proteins by SLCP treatment in comparison to Cur indicates SLCP is a stronger negative regulator on these proteins, which suggests that a greater amount of Cur is required to inhibit mitophagy, as well as induction of cell death. Given that mitophagy may also be regulated by PINK-1/Parkin, we investigated the levels of PINK-1 after treatment with Cur and or SLCP. We found a significant reduction of PINK-1 levels (Figure 3), suggesting Cur- and or SLCP-induced mitophagy is PINK-1 dependent. Other than PINK-1, mitophagy may also be regulated by the Parkin pathway, but the role of Parkin in the regulation of cell death is debated. Importantly, PINK1 shuttles between the cytosol and mitochondria in healthy cells. It plays a vital role in communicating the collapse of the mitochondrial membrane potential and it can stabilize on the outer membrane of depolarized mitochondria and recruit Parkin, which is initially inactive. In addition, PINK1 can phosphorylate Parkin on the ubiquitin-like (UBL) domain, resulting in an increase of its ubiquitin ligase activity and the formation of polyubiquitin chains on the surface of depolarized mitochondrial membranes, which could act as a Parkin activator by overcoming the autoinhibitory mechanism of Parkin. Therefore, we investigated the levels of PINK1 rather than Parkin.In addition to macroautophagy and microautophagy, we also investigated the status of chaperone-mediated autophagy (CMA), which is a special type of autophagy for degradation of tiny proteins aggregates. It requires chaperones, such as heat shock cognate 70 (HSC70) and lysosome-associated membrane protein type 2A (LAMP-2A). Although HSC70 levels were unaltered, LAMP2A was significantly down regulated by Cur or SLCP, indicating CMA was also inhibited (Figure 5). In addition, we also checked whether the other chaperones, such as HSP70 and HSP90, were affected by Cur and or SLCP treatments in GBM cells. We observed that there was an upregulation of HSP70, whereas opposite effects were observed in the case of HSP90 in all these GBM cells (except F98 cells) after SLCP treatment. HSP90 become upregulated in cancer and the inhibition of HSP90 by Cur or SLCP suggested that Cur/SLCP acts as a HSP90-inhibitor [54].Previously, we have confirmed that the SLCP induced greater cell death in U-87MG cells by using MTT, TUNEL, Annexin-V staining, and comet assays [19]. In support of our previous findings, we presently observed more membrane blebbing, actin or cytoarchitectural damage, and chromosomal condensation (Figure S1), as well as induction of cell-death related proteins and reduction of cell survival proteins (Figure 6) in the case of SLCP, when compared to Cur-treated cells. This finding indicates that a higher amount of Cur is required to damage the cells, which can be achieved more efficiently by SLCP treatments. Moreover, an increased number of autophagy vacuoles (Figure 7), chromosomal condensation, and membrane blebbing, as seen by TEM images (Figure S1), confirmed that SLCP can induce autophagy and cell death more efficiently than by using Cur (Figure 6). Extrapolating these results, we have assessed that Cur and SLCP have roles on autophagy mechanisms in cultured GBM cells, without affecting the rat glial tumor cell line (C6-glioma) or mouseneuroblastoma cell line (N2a cells). To this end, the C6-glioma and N2a cells that were treated with the same concentrations (25 µM) of Cur and/or SLCP consistently revealed the lowest levels of autophagy and cell death markers (Figure 2 and Figure 6), which suggests that Cur and SLCP can specifically target its therapeutic effects on GBM cells (Type-IV glioma), rather than glial tumor or neuroblastoma cells. In addition, during cellular stress, pro-survival and pro-death processes are concomitantly activated, which depends on the degree of stress. Mild cellular stress causes damage to a few mitochondria, which are rapidly sequestered by autophagosomes, whereas severe stress induces mitochondrial damage and autophagy is unable to efficiently clear this. During these circumstances, mitochondria release pro-death proteins, such as cytochrome c, apoptosis inducing factor (AIF) and SMAC/Diablo, that can activate the cell death pathway. As treatment of Cur/SLCP induced cellular stress, therefore, it can induce mitochondrial damage and activate the cell death pathway. Overall, Cur or SLCP treatment induced cellular stress, which interfered in autophagy, mitophagy, and the cell death and survival pathway as observed in cultured GBM cells.As autophagy determines cell death and survivability, therefore, the role of autophagy in GBM cell death and survivability after Cur and SLCP treatment needs to be critically analyzed. In fact, not only under disease conditions, but even under normal physiological conditions, the autophagy mechanism is active and can promote cell death or increase cell growth. For example, nutrient starvation, deprivation of supporting factors, or a hypoxic environment increases cell survivability [55,56]. Similarly, autophagy-dependent program cell death also occurs during mammalian embryogenesis [57] and in the case of apoptosis-resistant cells, such as in the absence of the pro-apoptotic proteins, Bax and Bak [58]. Moreover, many cellular environment autophagy cross-talks with the apoptotic machineries and directly inhibits apoptosis [59]. Therefore, the connections between autophagy and cell death are very complicated and controversial. In the case of cancer cells, autophagy may act as a tumor suppressor, as well as inducing tumor growth [60]. Some reports suggest that induction of autophagy can suppress tumor growth, whereas its prolonged activation may kill cancer cells with a high apoptotic threshold. In contrast, prolonged inhibition of autophagy may lead to cell survival instead of cell death. Most interestingly, the apoptotic pathways become mutated in humantumors, where autophagy plays alternative forms of PCD to prevent their growth. In our study, we found an induction of autophagy by Cur and or SLCP treatment, but whether autophagy was the mechanism by which GBM cells were dying (cell death by autophagy) or autophagy was present during cell death (cell death with autophagy) is an open question. As we know, when cell death is mediated by autophagy and if the cell death is prevented after inhibition of autophagy, then it is considered as “autophagic cell death”. In our study, we did not investigate the cell death after inhibition of the autophagy mechanism, therefore, we were not sure whether it was a “autophagic cell death”. However, the “autophagic cell death” is also characterized by the presence of abundant autophagosomes and lack of phagocytic activities, and we found many autophagosomes in U-87MG cells after treatment with Cur and or SLCP (Figure 7), which suggests that Cur and or SLCP may have partially induced cell death caused by autophagy, along with apoptotic death [19]. However, we prefer to describe this phenomenon as “cell death with autophagy” rather than an important effector mechanism of cell death because we do not have concrete evidence to confirm whether the cell death was caused by autophagy. Most importantly, Cur and/or SLCP treatment caused DNA damage [19], and disruption of the cytoskeleton (Figure S1), which induced autophagy and suppress tumor growth, suggesting that these treatments have a negative impact on GBM cell survivability. Therefore, further experiments are needed for a better understanding of the role of autophagy mechanisms on GBM cell death and survival after treatment with Cur and or SLCP in order to apply its beneficial role for GBM therapy.
4. Materials and Methods
4.1. Chemicals
Curcumin (Purity >65%; catalog no: C1386-50G (Sigma, St. Louis, MO, USA), propidium iodide (PI), and other accessory chemicals were procured from Sigma (St. Louis, MO, USA). Hoechst 33342 was purchased from ThermoFisher Scientific (Grand Island, NY, USA). Solid lipid particles containing Cur (SLCP or Longvida, which contains 26% pure Cur) were gifted from Verdure Sciences (Noblesville, IN, USA). The SLCP has been well characterized by us and others in collaboration with Verdure Sciences, including clinical studies in Alzheimer’s disease [19,27]. The human origin GBM cell line (U-87MG; catalog no: HTB-14), rat GBM cells (F98, catalog no: ATCC® CRL2397™), mouseglioma (C6-glioma, catalog no: ATCC® CCL107™), and N2a (catalog no: ATCC® CCL-131™) cells were purchased from ATCC (Manassas, VA, USA), whereas the mouse GBM cell line (GL261) was procured from DCTD/DTP Tumor Repository at the National Cancer Institute. All the antibodies used in this study are documented in Table 1.
Table 1
Sources of different antibodies used in this study.
Antibodies
Source
Type
Company
Catalog No.
Address
Atg5
Rabbit
Monoclonal
Cell signaling Technology
12994S
Danvers, MA, USA
Atg7
Rabbit
Monoclonal
Cell signaling Technology
8558S
Danvers, MA, USA
Beclin-1
Rabbit
Polyclonal
Cell signaling Technology
3738S
Danvers, MA, USA
LC3A/B
Rabbit
Polyclonal
Cell signaling Technology
4108S
Danvers, MA, USA
p62
Rabbit
Polyclonal
Cell signaling Technology
5114S
Danvers, MA, USA
mTOR
Rabbit
Polyclonal
Cell signaling Technology
2972S
Danvers, MA, USA
p-mTOR
Rabbit
Monoclonal
Cell signaling Technology
2971S
Danvers, MA, USA
PI3Kp85
Rabbit
Monoclonal
Cell signaling Technology
4292S
Danvers, MA, USA
BNIP3L/NIX
Rabbit
Monoclonal
Cell signaling Technology
12396S
Danvers, MA, USA
FUNDC1
Rabbit
Monoclonal
EMD Millipore
ABC506
Burlington, MA, USA
HIF-1α
Rabbit
Monoclonal
Cell signaling Technology
14179S
Danvers, MA, USA
PINK-1
Rabbit
Monoclonal
Cell signaling Technology
6946S
Danvers, MA, USA
Cyt-c
Rabbit
Monoclonal
Cell Signaling Technology
4272S
Danvers, MA, USA
Caspase-3
Rabbit
Monoclonal
Cell Signaling Technology
9661S
Danvers, MA, USA
Bax
Rabbit
Polyclonal
Cell signaling Technology
2772S
Danvers, MA, USA
Bcl-2
Mouse
Monoclonal
Santa Cruz Biotech
Sc-7382
Santa Cruz, CA, USA
Akt
Rabbit
Monoclonal
Cell signaling Technology
9272S
Danvers, MA, USA
pAkt (Ser473)
Rabbit
Monoclonal
Cell signaling Technology
4060S
Danvers, MA, USA
HSP70
Rabbit
Polyclonal
Cell signaling Technology
4872S
Danvers, MA, USA
HSP90
Rabbit
Polyclonal
Cell signaling Technology
4877S
Danvers, MA, USA
HSC70
Rabbit
Polyclonal
Cell signaling Technology
8444S
Danvers, MA, USA
LAMP2
Mouse
Polyclonal
Santa Cruz Biotech
sc-20004
Santa Cruz, CA, USA
GAPDH
Rabbit
Monoclonal
Cell signaling Technology
2118S
Danvers, MA, USA
β-tubulin
Rabbit
Monoclonal
Cell signaling Technology
2146S
Danvers, MA, USA
4.2. Cell Culture
U-87MG and N2a cells were grown with Eagle’s Minimum Essential Medium (EMEM, GIBCO) containing 10% heat-inactivated fetal bovine serum (FBS), and penicillin/streptomycin (100 IU/mL penicillin and 100 µg streptomycin/mL). The Gl261 cells were cultured in Roswell Park Memorial Institute Medium-1640 (RPMI-1640), along with 10% FBS and pen/strep (100 IU/mL penicillin and 100 µg streptomycin/mL), and F98 cells were grown on Dulbeco’s Modified Eagle’s Medium (DMEM), along with 10% FBS and pen/strep, (100 IU/mL penicillin and 100 µg streptomycin/mL). The C6-glioma cells were grown in F12K media along with 2.5% FBS and 15% horse serum and 100 IU/mL penicillin and 100 µg streptomycin/mL. The cultures were maintained at 37 °C in a humidified atmosphere at 5% CO2. Prior to the experiment, the cells were grown either in a 75 cm2 culture flask, or on glass cover slips, with fresh media and antibiotics, but without growth factors, depending on the experimental setup.
4.3. Curcumin and or SLCP Treatment
Cur was solubilized in pure methanol (100%), as described previously (28), and then diluted in the Hank’s balanced salt solution (HBSS) to obtain its desired concentration before being added to the culture flask containing the cells. The final methanol concentration was ≤0.1% and the same amount of methanol was added to the vehicle-treated cell. The final Cur or SLCP concentration was 25 µM. This dose was selected on the basis of our dose dependent cell viability data (Figure S1) [34].
4.4. Immunocytochemistry and Confocal Imaging of Autophagy Markers.
Immunocytochemistry of Atg5, Atg7, Beclin-1, and LC3A/B were performed as described previously [24]. Briefly, U-87MG and N2a cells were grown (1 × 105/well) on a Petri-plate containing glass cover slips in EMEM with pen/strep (100 IU/mL penicillin and 100 µg streptomycin/mL) for 24 h and then treated with Cur and/or SLCP (25 µM) for another 24 h. Then, the cells were fixed with 4% paraformaldehyde after washing with cold PBS (0.1 mM, pH 7.4) and incubated with rabbit anti-Atg5, Atg7, Beclin-1, and LC3A/B monoclonal and polyclonal antibodies (1:200, see Table 1) overnight at 4 °C, followed by incubation with the respective secondary antibodies (1:500) tagged with Alexa-fluorophore 560 (Molecular Probes, OR) for 1 h at room temperature. Nuclei were stained with Hoechst 33342 (20 mM, ThermoFisher Scientific, Grand Island, NY, USA) for 5 min and visualized using a table top Fluoview confocal laser scanning microscope (FV1oi, Olympus) using appropriate filters for excitation and emission.
4.5. Transmission Electron Microscopy (TEM)
U-87MG cells were processed for TEM as described by Schrand and colleagues [61]. Briefly, U-87MG cells were grown in 60 mm Petri plate (~106 cells/mL) in EMEM with pen/strep (100 IU/mL penicillin and 100 µg streptomycin/mL) for 24 h. The next day, the cells were treated with Cur and or SLCP (25 µM) for 24 h. After treatment, the cells were thoroughly rinsed with fresh serum free media at room temperature (RT) for 3 times, 5 min each. Then, the cells were treated with 0.25% trypsin-EDTA solution for 1–2 min and the cell suspension was taken in a 15 mL conical tube and centrifuged for 5 min at 1000× g at room temperature. Supernatant was removed and 1 mL of fresh 2.5% glutaraldehyde/formaldehyde (dissolved in 0.1 mM PBS, pH 7.4) was added and kept for 2 h at RT. After fixation, the cells were thoroughly rinse with PBS, three times for 10 min each, and 1 mL of 1% osmium tetroxide (dissolved in PBS) was added and allowed for 1 h at RT. Then, the cell pellet was rinsed in PBS five times for 10 min each and then washed in double-distilled water (ddH2O) two times for 10 min each. After centrifugation, the cell pellet was dehydrated through a graded series of ethanol concentrations (50%, 70%, 90%, and 100%) for 10 min each. The cells were treated with propylene oxide: ethanol mixture (1:1) for 30–45 min, then this mixture was replaced with 100% propylene oxide for 10 min, followed by a propylene oxide: resin (1:1) for 45 min before continuing in 100% resin overnight. The sample block was prepared with small plastic cubes at the flat face and cells reached the bottom of the capsule. For sectioning, stereomicroscope lenses were adjusted to the lowest magnification and the lighting was set to focus on the sample. A glass knife was inserted into the knife holder and positioned near the sample block face in the ultramicrotome. The block was trimmed manually by advancing the glass knife attached to the ultra-microtome while viewing the sample through the stereomicroscope lenses. An 80-nm thick section was made, and several sections were collected onto a TEM grid (300-mesh Cu, with support film such as formvar/carbon) and sections on grids were allowed to dry for a few minutes, then carefully placed in a grid storage box using fine-tipped tweezers. For staining, a piece of parafilm was placed in a glass petri dish, onto which a few drops of water or stain were added. Then, the grid was placed face down on a drop of ddH2O for 1–2 min. Then, the grid was transferred face down onto a drop of 1% uranyl acetate and lead acetate (filtered through a 0.2-μm syringe filter) for 30 min, followed by the grid being dipped into a drop of double distilled H2O to rinse. Then, the grids were blot dried using Whatman’s filter paper and it was placed in a grid box for storage until imaging. At least 10 individual cells were imaged from each group and the number of autophagy vacuoles were counted from each of the cells manually.
4.6. Western Blot
To investigate different autophagy markers, Western blot was performed as described previously [19,24]. Briefly, after the stipulated period of each experiment, the media was removed and U-87MG, GL261, and F98 cells were washed with cold PBS, scrapped, collected in Eppendorf tubes, centrifuged, and pellets were lysed with cold radio-immunoprecipitation assay (RIPA) buffer, along with protease and phosphatase inhibitors. Total protein was measured from each of the samples by Pierce protein assay reagent. Equal amounts of protein, per lane, were loaded and electrophoresed on 10% Tris-glycine gel and transferred to PVDF membrane (Millipore, Bedford, MA). After probing with respective primary (1:1000; see Table 1) and secondary antibodies, the blots were developed with ImmobilonTM Western Chemiluminescent HRP-substrate (Millipore, Billeria, MA). The images were taken by a gel documentation system (Bio-Rad) with an automated exposure time. The relative optical density (OD) was measured using Image-J software (https://imagej.nih.gov/ij/). To ensure equal protein loading in each lane, the blots were probed with either β-tubulin or GAPDH.
4.7. Statistical Analysis
The data were expressed as mean ± SEM. Data were analyzed using one-way analysis of variance (ANOVA), followed by post-hoc Tukey HSD (honestly significant difference) test. Probability ≤0.05 was considered as statistically significant.
5. Conclusions
Overall, we demonstrated that Cur and or SLCP treatment induced autophagy and reduced mitophagy, probably through inhibition of the PI3K-Akt/mTOR signaling pathway in cultured GBM cells. In addition, cell death markers were induced, and cell survival markers were down-regulated by Cur and or SLCP. Importantly, SLCP showed greater induction of autophagy and greater inhibition of mitophagy markers, along with greater disruption of the PI3K-Akt/mTOR signaling pathway than Cur. There were lowest treatment effects on autophagy and mitophagy in rat glial tumor cells and mouseneuroblastoma cells. Therefore, the data presented demonstrated that induction of autophagy and reduction of mitophagy by Cur and or SLCP treatment, suggesting that treatments with SLCP to prevent GBM cell growth and proliferation may have promising clinical utility.
Authors: Monica Benvenuto; Loredana Albonici; Chiara Focaccetti; Sara Ciuffa; Sara Fazi; Loredana Cifaldi; Martino Tony Miele; Fernando De Maio; Ilaria Tresoldi; Vittorio Manzari; Andrea Modesti; Laura Masuelli; Roberto Bei Journal: Int J Mol Sci Date: 2020-09-10 Impact factor: 5.923
Authors: Daniel J Klionsky; Amal Kamal Abdel-Aziz; Sara Abdelfatah; Mahmoud Abdellatif; Asghar Abdoli; Steffen Abel; Hagai Abeliovich; Marie H Abildgaard; Yakubu Princely Abudu; Abraham Acevedo-Arozena; Iannis E Adamopoulos; Khosrow Adeli; Timon E Adolph; Annagrazia Adornetto; Elma Aflaki; Galila Agam; Anupam Agarwal; Bharat B Aggarwal; Maria Agnello; Patrizia Agostinis; Javed N Agrewala; Alexander Agrotis; Patricia V Aguilar; S Tariq Ahmad; Zubair M Ahmed; Ulises Ahumada-Castro; Sonja Aits; Shu Aizawa; Yunus Akkoc; Tonia Akoumianaki; Hafize Aysin Akpinar; Ahmed M Al-Abd; Lina Al-Akra; Abeer Al-Gharaibeh; Moulay A Alaoui-Jamali; Simon Alberti; Elísabet Alcocer-Gómez; Cristiano Alessandri; Muhammad Ali; M Abdul Alim Al-Bari; Saeb Aliwaini; Javad Alizadeh; Eugènia Almacellas; Alexandru Almasan; Alicia Alonso; Guillermo D Alonso; Nihal Altan-Bonnet; Dario C Altieri; Élida M C Álvarez; Sara Alves; Cristine Alves da Costa; Mazen M Alzaharna; Marialaura Amadio; Consuelo Amantini; Cristina Amaral; Susanna Ambrosio; Amal O Amer; Veena Ammanathan; Zhenyi An; Stig U Andersen; Shaida A Andrabi; Magaiver Andrade-Silva; Allen M Andres; Sabrina Angelini; David Ann; Uche C Anozie; Mohammad Y Ansari; Pedro Antas; Adam Antebi; Zuriñe Antón; Tahira Anwar; Lionel Apetoh; Nadezda Apostolova; Toshiyuki Araki; Yasuhiro Araki; Kohei Arasaki; Wagner L Araújo; Jun Araya; Catherine Arden; Maria-Angeles Arévalo; Sandro Arguelles; Esperanza Arias; Jyothi Arikkath; Hirokazu Arimoto; Aileen R Ariosa; Darius Armstrong-James; Laetitia Arnauné-Pelloquin; Angeles Aroca; Daniela S Arroyo; Ivica Arsov; Rubén Artero; Dalia Maria Lucia Asaro; Michael Aschner; Milad Ashrafizadeh; Osnat Ashur-Fabian; Atanas G Atanasov; Alicia K Au; Patrick Auberger; Holger W Auner; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Yenniffer Ávalos; Sanja Aveic; Célia Alexandra Aveleira; Tamar Avin-Wittenberg; Yucel Aydin; Scott Ayton; Srinivas Ayyadevara; Maria Azzopardi; Misuzu Baba; Jonathan M Backer; Steven K Backues; Dong-Hun Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Ahruem Baek; Seung-Hoon Baek; Sung Hee Baek; Giacinto Bagetta; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xiyuan Bai; Yidong Bai; Nandadulal Bairagi; Shounak Baksi; Teresa Balbi; Cosima T Baldari; Walter Balduini; Andrea Ballabio; Maria Ballester; Salma Balazadeh; Rena Balzan; Rina Bandopadhyay; Sreeparna Banerjee; Sulagna Banerjee; Ágnes Bánréti; Yan Bao; Mauricio S Baptista; Alessandra Baracca; Cristiana Barbati; Ariadna Bargiela; Daniela Barilà; Peter G Barlow; Sami J Barmada; Esther Barreiro; George E Barreto; Jiri Bartek; Bonnie Bartel; Alberto Bartolome; Gaurav R Barve; Suresh H Basagoudanavar; Diane C Bassham; Robert C Bast; Alakananda Basu; Henri Batoko; Isabella Batten; Etienne E Baulieu; Bradley L Baumgarner; Jagadeesh Bayry; Rupert Beale; Isabelle Beau; Florian Beaumatin; Luiz R G Bechara; George R Beck; Michael F Beers; Jakob Begun; Christian Behrends; Georg M N Behrens; Roberto Bei; Eloy Bejarano; Shai Bel; Christian Behl; Amine Belaid; Naïma Belgareh-Touzé; Cristina Bellarosa; Francesca Belleudi; Melissa Belló Pérez; Raquel Bello-Morales; Jackeline Soares de Oliveira Beltran; Sebastián Beltran; Doris Mangiaracina Benbrook; Mykolas Bendorius; Bruno A Benitez; Irene Benito-Cuesta; Julien Bensalem; Martin W Berchtold; Sabina Berezowska; Daniele Bergamaschi; Matteo Bergami; Andreas Bergmann; Laura Berliocchi; Clarisse Berlioz-Torrent; Amélie Bernard; Lionel Berthoux; Cagri G Besirli; Sebastien Besteiro; Virginie M Betin; Rudi Beyaert; Jelena S Bezbradica; Kiran Bhaskar; Ingrid Bhatia-Kissova; Resham Bhattacharya; Sujoy Bhattacharya; Shalmoli Bhattacharyya; Md Shenuarin Bhuiyan; Sujit Kumar Bhutia; Lanrong Bi; Xiaolin Bi; Trevor J Biden; Krikor Bijian; Viktor A Billes; Nadine Binart; Claudia Bincoletto; Asa B Birgisdottir; Geir Bjorkoy; Gonzalo Blanco; Ana Blas-Garcia; Janusz Blasiak; Robert Blomgran; Klas Blomgren; Janice S Blum; Emilio Boada-Romero; Mirta Boban; Kathleen Boesze-Battaglia; Philippe Boeuf; Barry Boland; Pascale Bomont; Paolo Bonaldo; Srinivasa Reddy Bonam; Laura Bonfili; Juan S Bonifacino; Brian A Boone; Martin D Bootman; Matteo Bordi; Christoph Borner; Beat C Bornhauser; Gautam Borthakur; Jürgen Bosch; Santanu Bose; Luis M Botana; Juan Botas; Chantal M Boulanger; Michael E Boulton; Mathieu Bourdenx; Benjamin Bourgeois; Nollaig M Bourke; Guilhem Bousquet; Patricia Boya; Peter V Bozhkov; Luiz H M Bozi; Tolga O Bozkurt; Doug E Brackney; Christian H Brandts; Ralf J Braun; Gerhard H Braus; Roberto Bravo-Sagua; José M Bravo-San Pedro; Patrick Brest; Marie-Agnès Bringer; Alfredo Briones-Herrera; V Courtney Broaddus; Peter Brodersen; Jeffrey L Brodsky; Steven L Brody; Paola G Bronson; Jeff M Bronstein; Carolyn N Brown; Rhoderick E Brown; Patricia C Brum; John H Brumell; Nicola Brunetti-Pierri; Daniele Bruno; Robert J Bryson-Richardson; Cecilia Bucci; Carmen Buchrieser; Marta Bueno; Laura Elisa Buitrago-Molina; Simone Buraschi; Shilpa Buch; J Ross Buchan; Erin M Buckingham; Hikmet Budak; Mauricio Budini; Geert Bultynck; Florin Burada; Joseph R Burgoyne; M Isabel Burón; Victor Bustos; Sabrina Büttner; Elena Butturini; Aaron Byrd; Isabel Cabas; Sandra Cabrera-Benitez; Ken Cadwell; Jingjing Cai; Lu Cai; Qian Cai; Montserrat Cairó; Jose A Calbet; Guy A Caldwell; Kim A Caldwell; Jarrod A Call; Riccardo Calvani; Ana C Calvo; Miguel Calvo-Rubio Barrera; Niels Os Camara; Jacques H Camonis; Nadine Camougrand; Michelangelo Campanella; Edward M Campbell; François-Xavier Campbell-Valois; Silvia Campello; Ilaria Campesi; Juliane C Campos; Olivier Camuzard; Jorge Cancino; Danilo Candido de Almeida; Laura Canesi; Isabella Caniggia; Barbara Canonico; Carles Cantí; Bin Cao; Michele Caraglia; Beatriz Caramés; Evie H Carchman; Elena Cardenal-Muñoz; Cesar Cardenas; Luis Cardenas; Sandra M Cardoso; Jennifer S Carew; Georges F Carle; Gillian Carleton; Silvia Carloni; Didac Carmona-Gutierrez; Leticia A Carneiro; Oliana Carnevali; Julian M Carosi; Serena Carra; Alice Carrier; Lucie Carrier; Bernadette Carroll; A Brent Carter; Andreia Neves Carvalho; Magali Casanova; Caty Casas; Josefina Casas; Chiara Cassioli; Eliseo F Castillo; Karen Castillo; Sonia Castillo-Lluva; Francesca Castoldi; Marco Castori; Ariel F Castro; Margarida Castro-Caldas; Javier Castro-Hernandez; Susana Castro-Obregon; Sergio D Catz; Claudia Cavadas; Federica Cavaliere; Gabriella Cavallini; Maria Cavinato; Maria L Cayuela; Paula Cebollada Rica; Valentina Cecarini; Francesco Cecconi; Marzanna Cechowska-Pasko; Simone Cenci; Victòria Ceperuelo-Mallafré; João J Cerqueira; Janete M Cerutti; Davide Cervia; Vildan Bozok Cetintas; Silvia Cetrullo; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Oishee Chakrabarti; Tapas Chakraborty; Trinad Chakraborty; Mounia Chami; Georgios Chamilos; David W Chan; Edmond Y W Chan; Edward D Chan; H Y Edwin Chan; Helen H Chan; Hung Chan; Matthew T V Chan; Yau Sang Chan; Partha K Chandra; Chih-Peng Chang; Chunmei Chang; Hao-Chun Chang; Kai Chang; Jie Chao; Tracey Chapman; Nicolas Charlet-Berguerand; Samrat Chatterjee; Shail K Chaube; Anu Chaudhary; Santosh Chauhan; Edward Chaum; Frédéric Checler; Michael E Cheetham; Chang-Shi Chen; Guang-Chao Chen; Jian-Fu Chen; Liam L Chen; Leilei Chen; Lin Chen; Mingliang Chen; Mu-Kuan Chen; Ning Chen; Quan Chen; Ruey-Hwa Chen; Shi Chen; Wei Chen; Weiqiang Chen; Xin-Ming Chen; Xiong-Wen Chen; Xu Chen; Yan Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Yue-Qin Chen; Zhefan Stephen Chen; Zhi Chen; Zhi-Hua Chen; Zhijian J Chen; Zhixiang Chen; Hanhua Cheng; Jun Cheng; Shi-Yuan Cheng; Wei Cheng; Xiaodong Cheng; Xiu-Tang Cheng; Yiyun Cheng; Zhiyong Cheng; Zhong Chen; Heesun Cheong; Jit Kong Cheong; Boris V Chernyak; Sara Cherry; Chi Fai Randy Cheung; Chun Hei Antonio Cheung; King-Ho Cheung; Eric Chevet; Richard J Chi; Alan Kwok Shing Chiang; Ferdinando Chiaradonna; Roberto Chiarelli; Mario Chiariello; Nathalia Chica; Susanna Chiocca; Mario Chiong; Shih-Hwa Chiou; Abhilash I Chiramel; Valerio Chiurchiù; Dong-Hyung Cho; Seong-Kyu Choe; Augustine M K Choi; Mary E Choi; Kamalika Roy Choudhury; Norman S Chow; Charleen T Chu; Jason P Chua; John Jia En Chua; Hyewon Chung; Kin Pan Chung; Seockhoon Chung; So-Hyang Chung; Yuen-Li Chung; Valentina Cianfanelli; Iwona A Ciechomska; Mariana Cifuentes; Laura Cinque; Sebahattin Cirak; Mara Cirone; Michael J Clague; Robert Clarke; Emilio Clementi; Eliana M Coccia; Patrice Codogno; Ehud Cohen; Mickael M Cohen; Tania Colasanti; Fiorella Colasuonno; Robert A Colbert; Anna Colell; Miodrag Čolić; Nuria S Coll; Mark O Collins; María I Colombo; Daniel A Colón-Ramos; Lydie Combaret; Sergio Comincini; Márcia R Cominetti; Antonella Consiglio; Andrea Conte; Fabrizio Conti; Viorica Raluca Contu; Mark R Cookson; Kevin M Coombs; Isabelle Coppens; Maria Tiziana Corasaniti; Dale P Corkery; Nils Cordes; Katia Cortese; Maria do Carmo Costa; Sarah Costantino; Paola Costelli; Ana Coto-Montes; Peter J Crack; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Riccardo Cristofani; Tamas Csizmadia; Antonio Cuadrado; Bing Cui; Jun Cui; Yixian Cui; Yong Cui; Emmanuel Culetto; Andrea C Cumino; Andrey V Cybulsky; Mark J Czaja; Stanislaw J Czuczwar; Stefania D'Adamo; Marcello D'Amelio; Daniela D'Arcangelo; Andrew C D'Lugos; Gabriella D'Orazi; James A da Silva; Hormos Salimi Dafsari; Ruben K Dagda; Yasin Dagdas; Maria Daglia; Xiaoxia Dai; Yun Dai; Yuyuan Dai; Jessica Dal Col; Paul Dalhaimer; Luisa Dalla Valle; Tobias Dallenga; Guillaume Dalmasso; Markus Damme; Ilaria Dando; Nico P Dantuma; April L Darling; Hiranmoy Das; Srinivasan Dasarathy; Santosh K Dasari; Srikanta Dash; Oliver Daumke; Adrian N Dauphinee; Jeffrey S Davies; Valeria A Dávila; Roger J Davis; Tanja Davis; Sharadha Dayalan Naidu; Francesca De Amicis; Karolien De Bosscher; Francesca De Felice; Lucia De Franceschi; Chiara De Leonibus; Mayara G de Mattos Barbosa; Guido R Y De Meyer; Angelo De Milito; Cosimo De Nunzio; Clara De Palma; Mauro De Santi; Claudio De Virgilio; Daniela De Zio; Jayanta Debnath; Brian J DeBosch; Jean-Paul Decuypere; Mark A Deehan; Gianluca Deflorian; James DeGregori; Benjamin Dehay; Gabriel Del Rio; Joe R Delaney; Lea M D Delbridge; Elizabeth Delorme-Axford; M Victoria Delpino; Francesca Demarchi; Vilma Dembitz; Nicholas D Demers; Hongbin Deng; Zhiqiang Deng; Joern Dengjel; Paul Dent; Donna Denton; Melvin L DePamphilis; Channing J Der; Vojo Deretic; Albert Descoteaux; Laura Devis; Sushil Devkota; Olivier Devuyst; Grant Dewson; Mahendiran Dharmasivam; Rohan Dhiman; Diego di Bernardo; Manlio Di Cristina; Fabio Di Domenico; Pietro Di Fazio; Alessio Di Fonzo; Giovanni Di Guardo; Gianni M Di Guglielmo; Luca Di Leo; Chiara Di Malta; Alessia Di Nardo; Martina Di Rienzo; Federica Di Sano; George Diallinas; Jiajie Diao; Guillermo Diaz-Araya; Inés Díaz-Laviada; Jared M Dickinson; Marc Diederich; Mélanie Dieudé; Ivan Dikic; Shiping Ding; Wen-Xing Ding; Luciana Dini; Jelena Dinić; Miroslav Dinic; Albena T Dinkova-Kostova; Marc S Dionne; Jörg H W Distler; Abhinav Diwan; Ian M C Dixon; Mojgan Djavaheri-Mergny; Ina Dobrinski; Oxana Dobrovinskaya; Radek Dobrowolski; Renwick C J Dobson; Jelena Đokić; Serap Dokmeci Emre; Massimo Donadelli; Bo Dong; Xiaonan Dong; Zhiwu Dong; Gerald W Dorn Ii; Volker Dotsch; Huan Dou; Juan Dou; Moataz Dowaidar; Sami Dridi; Liat Drucker; Ailian Du; Caigan Du; Guangwei Du; Hai-Ning Du; Li-Lin Du; André du Toit; Shao-Bin Duan; Xiaoqiong Duan; Sónia P Duarte; Anna Dubrovska; Elaine A Dunlop; Nicolas Dupont; Raúl V Durán; Bilikere S Dwarakanath; Sergey A Dyshlovoy; Darius Ebrahimi-Fakhari; Leopold Eckhart; Charles L Edelstein; Thomas Efferth; Eftekhar Eftekharpour; Ludwig Eichinger; Nabil Eid; Tobias Eisenberg; N Tony Eissa; Sanaa Eissa; Miriam Ejarque; Abdeljabar El Andaloussi; Nazira El-Hage; Shahenda El-Naggar; Anna Maria Eleuteri; Eman S El-Shafey; Mohamed Elgendy; Aristides G Eliopoulos; María M Elizalde; Philip M Elks; Hans-Peter Elsasser; Eslam S Elsherbiny; Brooke M Emerling; N C Tolga Emre; Christina H Eng; Nikolai Engedal; Anna-Mart Engelbrecht; Agnete S T Engelsen; Jorrit M Enserink; Ricardo Escalante; Audrey Esclatine; Mafalda Escobar-Henriques; Eeva-Liisa Eskelinen; Lucile Espert; Makandjou-Ola Eusebio; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Francesco Facchiano; Bengt Fadeel; Claudio Fader; Alex C Faesen; W Douglas Fairlie; Alberto Falcó; Bjorn H Falkenburger; Daping Fan; Jie Fan; Yanbo Fan; Evandro F Fang; Yanshan Fang; Yognqi Fang; Manolis Fanto; Tamar Farfel-Becker; Mathias Faure; Gholamreza Fazeli; Anthony O Fedele; Arthur M Feldman; Du Feng; Jiachun Feng; Lifeng Feng; Yibin Feng; Yuchen Feng; Wei Feng; Thais Fenz Araujo; Thomas A Ferguson; Álvaro F Fernández; Jose C Fernandez-Checa; Sonia Fernández-Veledo; Alisdair R Fernie; Anthony W Ferrante; Alessandra Ferraresi; Merari F Ferrari; Julio C B Ferreira; Susan Ferro-Novick; Antonio Figueras; Riccardo Filadi; Nicoletta Filigheddu; Eduardo Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; Vittorio Fineschi; Francesca Finetti; Steven Finkbeiner; Edward A Fisher; Paul B Fisher; Flavio Flamigni; Steven J Fliesler; Trude H Flo; Ida Florance; Oliver Florey; Tullio Florio; Erika Fodor; Carlo Follo; Edward A Fon; Antonella Forlino; Francesco Fornai; Paola Fortini; Anna Fracassi; Alessandro Fraldi; Brunella Franco; Rodrigo Franco; Flavia Franconi; Lisa B Frankel; Scott L Friedman; Leopold F Fröhlich; Gema Frühbeck; Jose M Fuentes; Yukio Fujiki; Naonobu Fujita; Yuuki Fujiwara; Mitsunori Fukuda; Simone Fulda; Luc Furic; Norihiko Furuya; Carmela Fusco; Michaela U Gack; Lidia Gaffke; Sehamuddin Galadari; Alessia Galasso; Maria F Galindo; Sachith Gallolu Kankanamalage; Lorenzo Galluzzi; Vincent Galy; Noor Gammoh; Boyi Gan; Ian G Ganley; Feng Gao; Hui Gao; Minghui Gao; Ping Gao; Shou-Jiang Gao; Wentao Gao; Xiaobo Gao; Ana Garcera; Maria Noé Garcia; Verónica E Garcia; Francisco García-Del Portillo; Vega Garcia-Escudero; Aracely Garcia-Garcia; Marina Garcia-Macia; Diana García-Moreno; Carmen Garcia-Ruiz; Patricia García-Sanz; Abhishek D Garg; Ricardo Gargini; Tina Garofalo; Robert F Garry; Nils C Gassen; Damian Gatica; Liang Ge; Wanzhong Ge; Ruth Geiss-Friedlander; Cecilia Gelfi; Pascal Genschik; Ian E Gentle; Valeria Gerbino; Christoph Gerhardt; Kyla Germain; Marc Germain; David A Gewirtz; Elham Ghasemipour Afshar; Saeid Ghavami; Alessandra Ghigo; Manosij Ghosh; Georgios Giamas; Claudia Giampietri; Alexandra Giatromanolaki; Gary E Gibson; Spencer B Gibson; Vanessa Ginet; Edward Giniger; Carlotta Giorgi; Henrique Girao; Stephen E Girardin; Mridhula Giridharan; Sandy Giuliano; Cecilia Giulivi; Sylvie Giuriato; Julien Giustiniani; Alexander Gluschko; Veit Goder; Alexander Goginashvili; Jakub Golab; David C Goldstone; Anna Golebiewska; Luciana R Gomes; Rodrigo Gomez; Rubén Gómez-Sánchez; Maria Catalina Gomez-Puerto; Raquel Gomez-Sintes; Qingqiu Gong; Felix M Goni; Javier González-Gallego; Tomas Gonzalez-Hernandez; Rosa A Gonzalez-Polo; Jose A Gonzalez-Reyes; Patricia González-Rodríguez; Ing Swie Goping; Marina S Gorbatyuk; Nikolai V Gorbunov; Kıvanç Görgülü; Roxana M Gorojod; Sharon M Gorski; Sandro Goruppi; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Martin Graef; Markus H Gräler; Veronica Granatiero; Daniel Grasso; Joshua P Gray; Douglas R Green; Alexander Greenhough; Stephen L Gregory; Edward F Griffin; Mark W Grinstaff; Frederic Gros; Charles Grose; Angelina S Gross; Florian Gruber; Paolo Grumati; Tilman Grune; Xueyan Gu; Jun-Lin Guan; Carlos M Guardia; Kishore Guda; Flora Guerra; Consuelo Guerri; Prasun Guha; Carlos Guillén; Shashi Gujar; Anna Gukovskaya; Ilya Gukovsky; Jan Gunst; Andreas Günther; Anyonya R Guntur; Chuanyong Guo; Chun Guo; Hongqing Guo; Lian-Wang Guo; Ming Guo; Pawan Gupta; Shashi Kumar Gupta; Swapnil Gupta; Veer Bala Gupta; Vivek Gupta; Asa B Gustafsson; David D Gutterman; Ranjitha H B; Annakaisa Haapasalo; James E Haber; Aleksandra Hać; Shinji Hadano; Anders J Hafrén; Mansour Haidar; Belinda S Hall; Gunnel Halldén; Anne Hamacher-Brady; Andrea Hamann; Maho Hamasaki; Weidong Han; Malene Hansen; Phyllis I Hanson; Zijian Hao; Masaru Harada; Ljubica Harhaji-Trajkovic; Nirmala Hariharan; Nigil Haroon; James Harris; Takafumi Hasegawa; Noor Hasima Nagoor; Jeffrey A Haspel; Volker Haucke; Wayne D Hawkins; Bruce A Hay; Cole M Haynes; Soren B Hayrabedyan; Thomas S Hays; Congcong He; Qin He; Rong-Rong He; You-Wen He; Yu-Ying He; Yasser Heakal; Alexander M Heberle; J Fielding Hejtmancik; Gudmundur Vignir Helgason; Vanessa Henkel; Marc Herb; Alexander Hergovich; Anna Herman-Antosiewicz; Agustín Hernández; Carlos Hernandez; Sergio Hernandez-Diaz; Virginia Hernandez-Gea; Amaury Herpin; Judit Herreros; Javier H Hervás; Daniel Hesselson; Claudio Hetz; Volker T Heussler; Yujiro Higuchi; Sabine Hilfiker; Joseph A Hill; William S Hlavacek; Emmanuel A Ho; Idy H T Ho; Philip Wing-Lok Ho; Shu-Leong Ho; Wan Yun Ho; G Aaron Hobbs; Mark Hochstrasser; Peter H M Hoet; Daniel Hofius; Paul Hofman; Annika Höhn; Carina I Holmberg; Jose R Hombrebueno; Chang-Won Hong Yi-Ren Hong; Lora V Hooper; Thorsten Hoppe; Rastislav Horos; Yujin Hoshida; I-Lun Hsin; Hsin-Yun Hsu; Bing Hu; Dong Hu; Li-Fang Hu; Ming Chang Hu; Ronggui Hu; Wei Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Jinlian Hua; Yingqi Hua; Chongmin Huan; Canhua Huang; Chuanshu Huang; Chuanxin Huang; Chunling Huang; Haishan Huang; Kun Huang; Michael L H Huang; Rui Huang; Shan Huang; Tianzhi Huang; Xing Huang; Yuxiang Jack Huang; Tobias B Huber; Virginie Hubert; Christian A Hubner; Stephanie M Hughes; William E Hughes; Magali Humbert; Gerhard Hummer; James H Hurley; Sabah Hussain; Salik Hussain; Patrick J Hussey; Martina Hutabarat; Hui-Yun Hwang; Seungmin Hwang; Antonio Ieni; Fumiyo Ikeda; Yusuke Imagawa; Yuzuru Imai; Carol Imbriano; Masaya Imoto; Denise M Inman; Ken Inoki; Juan Iovanna; Renato V Iozzo; Giuseppe Ippolito; Javier E Irazoqui; Pablo Iribarren; Mohd Ishaq; Makoto Ishikawa; Nestor Ishimwe; Ciro Isidoro; Nahed Ismail; Shohreh Issazadeh-Navikas; Eisuke Itakura; Daisuke Ito; Davor Ivankovic; Saška Ivanova; Anand Krishnan V Iyer; José M Izquierdo; Masanori Izumi; Marja Jäättelä; Majid Sakhi Jabir; William T Jackson; Nadia Jacobo-Herrera; Anne-Claire Jacomin; Elise Jacquin; Pooja Jadiya; Hartmut Jaeschke; Chinnaswamy Jagannath; Arjen J Jakobi; Johan Jakobsson; Bassam Janji; Pidder Jansen-Dürr; Patric J Jansson; Jonathan Jantsch; Sławomir Januszewski; Alagie Jassey; Steve Jean; Hélène Jeltsch-David; Pavla Jendelova; Andreas Jenny; Thomas E Jensen; Niels Jessen; Jenna L Jewell; Jing Ji; Lijun Jia; Rui Jia; Liwen Jiang; Qing Jiang; Richeng Jiang; Teng Jiang; Xuejun Jiang; Yu Jiang; Maria Jimenez-Sanchez; Eun-Jung Jin; Fengyan Jin; Hongchuan Jin; Li Jin; Luqi Jin; Meiyan Jin; Si Jin; Eun-Kyeong Jo; Carine Joffre; Terje Johansen; Gail V W Johnson; Simon A Johnston; Eija Jokitalo; Mohit Kumar Jolly; Leo A B Joosten; Joaquin Jordan; Bertrand Joseph; Dianwen Ju; Jeong-Sun Ju; Jingfang Ju; Esmeralda Juárez; Delphine Judith; Gábor Juhász; Youngsoo Jun; Chang Hwa Jung; Sung-Chul Jung; Yong Keun Jung; Heinz Jungbluth; Johannes Jungverdorben; Steffen Just; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Daniel Kaganovich; Alon Kahana; Renate Kain; Shinjo Kajimura; Maria Kalamvoki; Manjula Kalia; Danuta S Kalinowski; Nina Kaludercic; Ioanna Kalvari; Joanna Kaminska; Vitaliy O Kaminskyy; Hiromitsu Kanamori; Keizo Kanasaki; Chanhee Kang; Rui Kang; Sang Sun Kang; Senthilvelrajan Kaniyappan; Tomotake Kanki; Thirumala-Devi Kanneganti; Anumantha G Kanthasamy; Arthi Kanthasamy; Marc Kantorow; Orsolya Kapuy; Michalis V Karamouzis; Md Razaul Karim; Parimal Karmakar; Rajesh G Katare; Masaru Kato; Stefan H E Kaufmann; Anu Kauppinen; Gur P Kaushal; Susmita Kaushik; Kiyoshi Kawasaki; Kemal Kazan; Po-Yuan Ke; Damien J Keating; Ursula Keber; John H Kehrl; Kate E Keller; Christian W Keller; Jongsook Kim Kemper; Candia M Kenific; Oliver Kepp; Stephanie Kermorgant; Andreas Kern; Robin Ketteler; Tom G Keulers; Boris Khalfin; Hany Khalil; Bilon Khambu; Shahid Y Khan; Vinoth Kumar Megraj Khandelwal; Rekha Khandia; Widuri Kho; Noopur V Khobrekar; Sataree Khuansuwan; Mukhran Khundadze; Samuel A Killackey; Dasol Kim; Deok Ryong Kim; Do-Hyung Kim; Dong-Eun Kim; Eun Young Kim; Eun-Kyoung Kim; Hak-Rim Kim; Hee-Sik Kim; Jeong Hun Kim; Jin Kyung Kim; Jin-Hoi Kim; Joungmok Kim; Ju Hwan Kim; Keun Il Kim; Peter K Kim; Seong-Jun Kim; Scot R Kimball; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Matthew A King; Kerri J Kinghorn; Conan G Kinsey; Vladimir Kirkin; Lorrie A Kirshenbaum; Sergey L Kiselev; Shuji Kishi; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Richard N Kitsis; Josef T Kittler; Ole Kjaerulff; Peter S Klein; Thomas Klopstock; Jochen Klucken; Helene Knævelsrud; Roland L Knorr; Ben C B Ko; Fred Ko; Jiunn-Liang Ko; Hotaka Kobayashi; Satoru Kobayashi; Ina Koch; Jan C Koch; Ulrich Koenig; Donat Kögel; Young Ho Koh; Masato Koike; Sepp D Kohlwein; Nur M Kocaturk; Masaaki Komatsu; Jeannette König; Toru Kono; Benjamin T Kopp; Tamas Korcsmaros; Gözde Korkmaz; Viktor I Korolchuk; Mónica Suárez Korsnes; Ali Koskela; Janaiah Kota; Yaichiro Kotake; Monica L Kotler; Yanjun Kou; Michael I Koukourakis; Evangelos Koustas; Attila L Kovacs; Tibor Kovács; Daisuke Koya; Tomohiro Kozako; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Anna D Krasnodembskaya; Carole Kretz-Remy; Guido Kroemer; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Sabine Kuenen; Lars Kuerschner; Thomas Kukar; Ajay Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Sharad Kumar; Shinji Kume; Caroline Kumsta; Chanakya N Kundu; Mondira Kundu; Ajaikumar B Kunnumakkara; Lukasz Kurgan; Tatiana G Kutateladze; Ozlem Kutlu; SeongAe Kwak; Ho Jeong Kwon; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert La Spada; Patrick Labonté; Sylvain Ladoire; Ilaria Laface; Frank Lafont; Diane C Lagace; Vikramjit Lahiri; Zhibing Lai; Angela S Laird; Aparna Lakkaraju; Trond Lamark; Sheng-Hui Lan; Ane Landajuela; Darius J R Lane; Jon D Lane; Charles H Lang; Carsten Lange; Ülo Langel; Rupert Langer; Pierre Lapaquette; Jocelyn Laporte; Nicholas F LaRusso; Isabel Lastres-Becker; Wilson Chun Yu Lau; Gordon W Laurie; Sergio Lavandero; Betty Yuen Kwan Law; Helen Ka-Wai Law; Rob Layfield; Weidong Le; Herve Le Stunff; Alexandre Y Leary; Jean-Jacques Lebrun; Lionel Y W Leck; Jean-Philippe Leduc-Gaudet; Changwook Lee; Chung-Pei Lee; Da-Hye Lee; Edward B Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Heung Kyu Lee; Jae Man Lee; Jason S Lee; Jin-A Lee; Joo-Yong Lee; Jun Hee Lee; Michael Lee; Min Goo Lee; Min Jae Lee; Myung-Shik Lee; Sang Yoon Lee; Seung-Jae Lee; Stella Y Lee; Sung Bae Lee; Won Hee Lee; Ying-Ray Lee; Yong-Ho Lee; Youngil Lee; Christophe Lefebvre; Renaud Legouis; Yu L Lei; Yuchen Lei; Sergey Leikin; Gerd Leitinger; Leticia Lemus; Shuilong Leng; Olivia Lenoir; Guido Lenz; Heinz Josef Lenz; Paola Lenzi; Yolanda León; Andréia M Leopoldino; Christoph Leschczyk; Stina Leskelä; Elisabeth Letellier; Chi-Ting Leung; Po Sing Leung; Jeremy S Leventhal; Beth Levine; Patrick A Lewis; Klaus Ley; Bin Li; Da-Qiang Li; Jianming Li; Jing Li; Jiong Li; Ke Li; Liwu Li; Mei Li; Min Li; Min Li; Ming Li; Mingchuan Li; Pin-Lan Li; Ming-Qing Li; Qing Li; Sheng Li; Tiangang Li; Wei Li; Wenming Li; Xue Li; Yi-Ping Li; Yuan Li; Zhiqiang Li; Zhiyong Li; Zhiyuan Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Weicheng Liang; Yongheng Liang; YongTian Liang; Guanghong Liao; Lujian Liao; Mingzhi Liao; Yung-Feng Liao; Mariangela Librizzi; Pearl P Y Lie; Mary A Lilly; Hyunjung J Lim; Thania R R Lima; Federica Limana; Chao Lin; Chih-Wen Lin; Dar-Shong Lin; Fu-Cheng Lin; Jiandie D Lin; Kurt M Lin; Kwang-Huei Lin; Liang-Tzung Lin; Pei-Hui Lin; Qiong Lin; Shaofeng Lin; Su-Ju Lin; Wenyu Lin; Xueying Lin; Yao-Xin Lin; Yee-Shin Lin; Rafael Linden; Paula Lindner; Shuo-Chien Ling; Paul Lingor; Amelia K Linnemann; Yih-Cherng Liou; Marta M Lipinski; Saška Lipovšek; Vitor A Lira; Natalia Lisiak; Paloma B Liton; Chao Liu; Ching-Hsuan Liu; Chun-Feng Liu; Cui Hua Liu; Fang Liu; Hao Liu; Hsiao-Sheng Liu; Hua-Feng Liu; Huifang Liu; Jia Liu; Jing Liu; Julia Liu; Leyuan Liu; Longhua Liu; Meilian Liu; Qin Liu; Wei Liu; Wende Liu; Xiao-Hong Liu; Xiaodong Liu; Xingguo Liu; Xu Liu; Xuedong Liu; Yanfen Liu; Yang Liu; Yang Liu; Yueyang Liu; Yule Liu; J Andrew Livingston; Gerard Lizard; Jose M Lizcano; Senka Ljubojevic-Holzer; Matilde E LLeonart; David Llobet-Navàs; Alicia Llorente; Chih Hung Lo; Damián Lobato-Márquez; Qi Long; Yun Chau Long; Ben Loos; Julia A Loos; Manuela G López; Guillermo López-Doménech; José Antonio López-Guerrero; Ana T López-Jiménez; Óscar López-Pérez; Israel López-Valero; Magdalena J Lorenowicz; Mar Lorente; Peter Lorincz; Laura Lossi; Sophie Lotersztajn; Penny E Lovat; Jonathan F Lovell; Alenka Lovy; Péter Lőw; Guang Lu; Haocheng Lu; Jia-Hong Lu; Jin-Jian Lu; Mengji Lu; Shuyan Lu; Alessandro Luciani; John M Lucocq; Paula Ludovico; Micah A Luftig; Morten Luhr; Diego Luis-Ravelo; Julian J Lum; Liany Luna-Dulcey; Anders H Lund; Viktor K Lund; Jan D Lünemann; Patrick Lüningschrör; Honglin Luo; Rongcan Luo; Shouqing Luo; Zhi Luo; Claudio Luparello; Bernhard Lüscher; Luan Luu; Alex Lyakhovich; Konstantin G Lyamzaev; Alf Håkon Lystad; Lyubomyr Lytvynchuk; Alvin C Ma; Changle Ma; Mengxiao Ma; Ning-Fang Ma; Quan-Hong Ma; Xinliang Ma; Yueyun Ma; Zhenyi Ma; Ormond A MacDougald; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; Sandra Maday; Frank Madeo; Muniswamy Madesh; Tobias Madl; Julio Madrigal-Matute; Akiko Maeda; Yasuhiro Maejima; Marta Magarinos; Poornima Mahavadi; Emiliano Maiani; Kenneth Maiese; Panchanan Maiti; Maria Chiara Maiuri; Barbara Majello; Michael B Major; Elena Makareeva; Fayaz Malik; Karthik Mallilankaraman; Walter Malorni; Alina Maloyan; Najiba Mammadova; Gene Chi Wai Man; Federico Manai; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Masoud H Manjili; Ravi Manjithaya; Patricio Manque; Bella B Manshian; Raquel Manzano; Claudia Manzoni; Kai Mao; Cinzia Marchese; Sandrine Marchetti; Anna Maria Marconi; Fabrizio Marcucci; Stefania Mardente; Olga A Mareninova; Marta Margeta; Muriel Mari; Sara Marinelli; Oliviero Marinelli; Guillermo Mariño; Sofia Mariotto; Richard S Marshall; Mark R Marten; Sascha Martens; Alexandre P J Martin; Katie R Martin; Sara Martin; Shaun Martin; Adrián Martín-Segura; Miguel A Martín-Acebes; Inmaculada Martin-Burriel; Marcos Martin-Rincon; Paloma Martin-Sanz; José A Martina; Wim Martinet; Aitor Martinez; Ana Martinez; Jennifer Martinez; Moises Martinez Velazquez; Nuria Martinez-Lopez; Marta Martinez-Vicente; Daniel O Martins; Joilson O Martins; Waleska K Martins; Tania Martins-Marques; Emanuele Marzetti; Shashank Masaldan; Celine Masclaux-Daubresse; Douglas G Mashek; Valentina Massa; Lourdes Massieu; Glenn R Masson; Laura Masuelli; Anatoliy I Masyuk; Tetyana V Masyuk; Paola Matarrese; Ander Matheu; Satoaki Matoba; Sachiko Matsuzaki; Pamela Mattar; Alessandro Matte; Domenico Mattoscio; José L Mauriz; Mario Mauthe; Caroline Mauvezin; Emanual Maverakis; Paola Maycotte; Johanna Mayer; Gianluigi Mazzoccoli; Cristina Mazzoni; Joseph R Mazzulli; Nami McCarty; Christine McDonald; Mitchell R McGill; Sharon L McKenna; BethAnn McLaughlin; Fionn McLoughlin; Mark A McNiven; Thomas G McWilliams; Fatima Mechta-Grigoriou; Tania Catarina Medeiros; Diego L Medina; Lynn A Megeney; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Alfred J Meijer; Annemarie H Meijer; Jakob Mejlvang; Alicia Meléndez; Annette Melk; Gonen Memisoglu; Alexandrina F Mendes; Delong Meng; Fei Meng; Tian Meng; Rubem Menna-Barreto; Manoj B Menon; Carol Mercer; Anne E Mercier; Jean-Louis Mergny; Adalberto Merighi; Seth D Merkley; Giuseppe Merla; Volker Meske; Ana Cecilia Mestre; Shree Padma Metur; Christian Meyer; Hemmo Meyer; Wenyi Mi; Jeanne Mialet-Perez; Junying Miao; Lucia Micale; Yasuo Miki; Enrico Milan; Małgorzata Milczarek; Dana L Miller; Samuel I Miller; Silke Miller; Steven W Millward; Ira Milosevic; Elena A Minina; Hamed Mirzaei; Hamid Reza Mirzaei; Mehdi Mirzaei; Amit Mishra; Nandita Mishra; Paras Kumar Mishra; Maja Misirkic Marjanovic; Roberta Misasi; Amit Misra; Gabriella Misso; Claire Mitchell; Geraldine Mitou; Tetsuji Miura; Shigeki Miyamoto; Makoto Miyazaki; Mitsunori Miyazaki; Taiga Miyazaki; Keisuke Miyazawa; Noboru Mizushima; Trine H Mogensen; Baharia Mograbi; Reza Mohammadinejad; Yasir Mohamud; Abhishek Mohanty; Sipra Mohapatra; Torsten Möhlmann; Asif Mohmmed; Anna Moles; Kelle H Moley; Maurizio Molinari; Vincenzo Mollace; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Costanza Montagna; Mervyn J Monteiro; Andrea Montella; L Ruth Montes; Barbara Montico; Vinod K Mony; Giacomo Monzio Compagnoni; Michael N Moore; Mohammad A Moosavi; Ana L Mora; Marina Mora; David Morales-Alamo; Rosario Moratalla; Paula I Moreira; Elena Morelli; Sandra Moreno; Daniel Moreno-Blas; Viviana Moresi; Benjamin Morga; Alwena H Morgan; Fabrice Morin; Hideaki Morishita; Orson L Moritz; Mariko Moriyama; Yuji Moriyasu; Manuela Morleo; Eugenia Morselli; Jose F Moruno-Manchon; Jorge Moscat; Serge Mostowy; Elisa Motori; Andrea Felinto Moura; Naima Moustaid-Moussa; Maria Mrakovcic; Gabriel Muciño-Hernández; Anupam Mukherjee; Subhadip Mukhopadhyay; Jean M Mulcahy Levy; Victoriano Mulero; Sylviane Muller; Christian Münch; Ashok Munjal; Pura Munoz-Canoves; Teresa Muñoz-Galdeano; Christian Münz; Tomokazu Murakawa; Claudia Muratori; Brona M Murphy; J Patrick Murphy; Aditya Murthy; Timo T Myöhänen; Indira U Mysorekar; Jennifer Mytych; Seyed Mohammad Nabavi; Massimo Nabissi; Péter Nagy; Jihoon Nah; Aimable Nahimana; Ichiro Nakagawa; Ken Nakamura; Hitoshi Nakatogawa; Shyam S Nandi; Meera Nanjundan; Monica Nanni; Gennaro Napolitano; Roberta Nardacci; Masashi Narita; Melissa Nassif; Ilana Nathan; Manabu Natsumeda; Ryno J Naude; Christin Naumann; Olaia Naveiras; Fatemeh Navid; Steffan T Nawrocki; Taras Y Nazarko; Francesca Nazio; Florentina Negoita; Thomas Neill; Amanda L Neisch; Luca M Neri; Mihai G Netea; Patrick Neubert; Thomas P Neufeld; Dietbert Neumann; Albert Neutzner; Phillip T Newton; Paul A Ney; Ioannis P Nezis; Charlene C W Ng; Tzi Bun Ng; Hang T T Nguyen; Long T Nguyen; Hong-Min Ni; Clíona Ní Cheallaigh; Zhenhong Ni; M Celeste Nicolao; Francesco Nicoli; Manuel Nieto-Diaz; Per Nilsson; Shunbin Ning; Rituraj Niranjan; Hiroshi Nishimune; Mireia Niso-Santano; Ralph A Nixon; Annalisa Nobili; Clevio Nobrega; Takeshi Noda; Uxía Nogueira-Recalde; Trevor M Nolan; Ivan Nombela; Ivana Novak; Beatriz Novoa; Takashi Nozawa; Nobuyuki Nukina; Carmen Nussbaum-Krammer; Jesper Nylandsted; Tracey R O'Donovan; Seónadh M O'Leary; Eyleen J O'Rourke; Mary P O'Sullivan; Timothy E O'Sullivan; Salvatore Oddo; Ina Oehme; Michinaga Ogawa; Eric Ogier-Denis; Margret H Ogmundsdottir; Besim Ogretmen; Goo Taeg Oh; Seon-Hee Oh; Young J Oh; Takashi Ohama; Yohei Ohashi; Masaki Ohmuraya; Vasileios Oikonomou; Rani Ojha; Koji Okamoto; Hitoshi Okazawa; Masahide Oku; Sara Oliván; Jorge M A Oliveira; Michael Ollmann; James A Olzmann; Shakib Omari; M Bishr Omary; Gizem Önal; Martin Ondrej; Sang-Bing Ong; Sang-Ging Ong; Anna Onnis; Juan A Orellana; Sara Orellana-Muñoz; Maria Del Mar Ortega-Villaizan; Xilma R Ortiz-Gonzalez; Elena Ortona; Heinz D Osiewacz; Abdel-Hamid K Osman; Rosario Osta; Marisa S Otegui; Kinya Otsu; Christiane Ott; Luisa Ottobrini; Jing-Hsiung James Ou; Tiago F Outeiro; Inger Oynebraten; Melek Ozturk; Gilles Pagès; Susanta Pahari; Marta Pajares; Utpal B Pajvani; Rituraj Pal; Simona Paladino; Nicolas Pallet; Michela Palmieri; Giuseppe Palmisano; Camilla Palumbo; Francesco Pampaloni; Lifeng Pan; Qingjun Pan; Wenliang Pan; Xin Pan; Ganna Panasyuk; Rahul Pandey; Udai B Pandey; Vrajesh Pandya; Francesco Paneni; Shirley Y Pang; Elisa Panzarini; Daniela L Papademetrio; Elena Papaleo; Daniel Papinski; Diana Papp; Eun Chan Park; Hwan Tae Park; Ji-Man Park; Jong-In Park; Joon Tae Park; Junsoo Park; Sang Chul Park; Sang-Youel Park; Abraham H Parola; Jan B Parys; Adrien Pasquier; Benoit Pasquier; João F Passos; Nunzia Pastore; Hemal H Patel; Daniel Patschan; Sophie Pattingre; Gustavo Pedraza-Alva; Jose Pedraza-Chaverri; Zully Pedrozo; Gang Pei; Jianming Pei; Hadas Peled-Zehavi; Joaquín M Pellegrini; Joffrey Pelletier; Miguel A Peñalva; Di Peng; Ying Peng; Fabio Penna; Maria Pennuto; Francesca Pentimalli; Cláudia Mf Pereira; Gustavo J S Pereira; Lilian C Pereira; Luis Pereira de Almeida; Nirma D Perera; Ángel Pérez-Lara; Ana B Perez-Oliva; María Esther Pérez-Pérez; Palsamy Periyasamy; Andras Perl; Cristiana Perrotta; Ida Perrotta; Richard G Pestell; Morten Petersen; Irina Petrache; Goran Petrovski; Thorsten Pfirrmann; Astrid S Pfister; Jennifer A Philips; Huifeng Pi; Anna Picca; Alicia M Pickrell; Sandy Picot; Giovanna M Pierantoni; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Karolina Pierzynowska; Federico Pietrocola; Miroslawa Pietruczuk; Claudio Pignata; Felipe X Pimentel-Muiños; Mario Pinar; Roberta O Pinheiro; Ronit Pinkas-Kramarski; Paolo Pinton; Karolina Pircs; Sujan Piya; Paola Pizzo; Theo S Plantinga; Harald W Platta; Ainhoa Plaza-Zabala; Markus Plomann; Egor Y Plotnikov; Helene Plun-Favreau; Ryszard Pluta; Roger Pocock; Stefanie Pöggeler; Christian Pohl; Marc Poirot; Angelo Poletti; Marisa Ponpuak; Hana Popelka; Blagovesta Popova; Helena Porta; Soledad Porte Alcon; Eliana Portilla-Fernandez; Martin Post; Malia B Potts; Joanna Poulton; Ted Powers; Veena Prahlad; Tomasz K Prajsnar; Domenico Praticò; Rosaria Prencipe; Muriel Priault; Tassula Proikas-Cezanne; Vasilis J Promponas; Christopher G Proud; Rosa Puertollano; Luigi Puglielli; Thomas Pulinilkunnil; Deepika Puri; Rajat Puri; Julien Puyal; Xiaopeng Qi; Yongmei Qi; Wenbin Qian; Lei Qiang; Yu Qiu; Joe Quadrilatero; Jorge Quarleri; Nina Raben; Hannah Rabinowich; Debora Ragona; Michael J Ragusa; Nader Rahimi; Marveh Rahmati; Valeria Raia; Nuno Raimundo; Namakkal-Soorappan Rajasekaran; Sriganesh Ramachandra Rao; Abdelhaq Rami; Ignacio Ramírez-Pardo; David B Ramsden; Felix Randow; Pundi N Rangarajan; Danilo Ranieri; Hai Rao; Lang Rao; Rekha Rao; Sumit Rathore; J Arjuna Ratnayaka; Edward A Ratovitski; Palaniyandi Ravanan; Gloria Ravegnini; Swapan K Ray; Babak Razani; Vito Rebecca; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; David Reigada; Jan H Reiling; Theo Rein; Siegfried Reipert; Rokeya Sultana Rekha; Hongmei Ren; Jun Ren; Weichao Ren; Tristan Renault; Giorgia Renga; Karen Reue; Kim Rewitz; Bruna Ribeiro de Andrade Ramos; S Amer Riazuddin; Teresa M Ribeiro-Rodrigues; Jean-Ehrland Ricci; Romeo Ricci; Victoria Riccio; Des R Richardson; Yasuko Rikihisa; Makarand V Risbud; Ruth M Risueño; Konstantinos Ritis; Salvatore Rizza; Rosario Rizzuto; Helen C Roberts; Luke D Roberts; Katherine J Robinson; Maria Carmela Roccheri; Stephane Rocchi; George G Rodney; Tiago Rodrigues; Vagner Ramon Rodrigues Silva; Amaia Rodriguez; Ruth Rodriguez-Barrueco; Nieves Rodriguez-Henche; Humberto Rodriguez-Rocha; Jeroen Roelofs; Robert S Rogers; Vladimir V Rogov; Ana I Rojo; Krzysztof Rolka; Vanina Romanello; Luigina Romani; Alessandra Romano; Patricia S Romano; David Romeo-Guitart; Luis C Romero; Montserrat Romero; Joseph C Roney; Christopher Rongo; Sante Roperto; Mathias T Rosenfeldt; Philip Rosenstiel; Anne G Rosenwald; Kevin A Roth; Lynn Roth; Steven Roth; Kasper M A Rouschop; Benoit D Roussel; Sophie Roux; Patrizia Rovere-Querini; Ajit Roy; Aurore Rozieres; Diego Ruano; David C Rubinsztein; Maria P Rubtsova; Klaus Ruckdeschel; Christoph Ruckenstuhl; Emil Rudolf; Rüdiger Rudolf; Alessandra Ruggieri; Avnika Ashok Ruparelia; Paola Rusmini; Ryan R Russell; Gian Luigi Russo; Maria Russo; Rossella Russo; Oxana O Ryabaya; Kevin M Ryan; Kwon-Yul Ryu; Maria Sabater-Arcis; Ulka Sachdev; Michael Sacher; Carsten Sachse; Abhishek Sadhu; Junichi Sadoshima; Nathaniel Safren; Paul Saftig; Antonia P Sagona; Gaurav Sahay; Amirhossein Sahebkar; Mustafa Sahin; Ozgur Sahin; Sumit Sahni; Nayuta Saito; Shigeru Saito; Tsunenori Saito; Ryohei Sakai; Yasuyoshi Sakai; Jun-Ichi Sakamaki; Kalle Saksela; Gloria Salazar; Anna Salazar-Degracia; Ghasem H Salekdeh; Ashok K Saluja; Belém Sampaio-Marques; Maria Cecilia Sanchez; Jose A Sanchez-Alcazar; Victoria Sanchez-Vera; Vanessa Sancho-Shimizu; J Thomas Sanderson; Marco Sandri; Stefano Santaguida; Laura Santambrogio; Magda M Santana; Giorgio Santoni; Alberto Sanz; Pascual Sanz; Shweta Saran; Marco Sardiello; Timothy J Sargeant; Apurva Sarin; Chinmoy Sarkar; Sovan Sarkar; Maria-Rosa Sarrias; Surajit Sarkar; Dipanka Tanu Sarmah; Jaakko Sarparanta; Aishwarya Sathyanarayan; Ranganayaki Sathyanarayanan; K Matthew Scaglione; Francesca Scatozza; Liliana Schaefer; Zachary T Schafer; Ulrich E Schaible; Anthony H V Schapira; Michael Scharl; Hermann M Schatzl; Catherine H Schein; Wiep Scheper; David Scheuring; Maria Vittoria Schiaffino; Monica Schiappacassi; Rainer Schindl; Uwe Schlattner; Oliver Schmidt; Roland Schmitt; Stephen D Schmidt; Ingo Schmitz; Eran Schmukler; Anja Schneider; Bianca E Schneider; Romana Schober; Alejandra C Schoijet; Micah B Schott; Michael Schramm; Bernd Schröder; Kai Schuh; Christoph Schüller; Ryan J Schulze; Lea Schürmanns; Jens C Schwamborn; Melanie Schwarten; Filippo Scialo; Sebastiano Sciarretta; Melanie J Scott; Kathleen W Scotto; A Ivana Scovassi; Andrea Scrima; Aurora Scrivo; David Sebastian; Salwa Sebti; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Iban Seiliez; Ekihiro Seki; Scott B Selleck; Frank W Sellke; Joshua T Selsby; Michael Sendtner; Serif Senturk; Elena Seranova; Consolato Sergi; Ruth Serra-Moreno; Hiromi Sesaki; Carmine Settembre; Subba Rao Gangi Setty; Gianluca Sgarbi; Ou Sha; John J Shacka; Javeed A Shah; Dantong Shang; Changshun Shao; Feng Shao; Soroush Sharbati; Lisa M Sharkey; Dipali Sharma; Gaurav Sharma; Kulbhushan Sharma; Pawan Sharma; Surendra Sharma; Han-Ming Shen; Hongtao Shen; Jiangang Shen; Ming Shen; Weili Shen; Zheni Shen; Rui Sheng; Zhi Sheng; Zu-Hang Sheng; Jianjian Shi; Xiaobing Shi; Ying-Hong Shi; Kahori Shiba-Fukushima; Jeng-Jer Shieh; Yohta Shimada; Shigeomi Shimizu; Makoto Shimozawa; Takahiro Shintani; Christopher J Shoemaker; Shahla Shojaei; Ikuo Shoji; Bhupendra V Shravage; Viji Shridhar; Chih-Wen Shu; Hong-Bing Shu; Ke Shui; Arvind K Shukla; Timothy E Shutt; Valentina Sica; Aleem Siddiqui; Amanda Sierra; Virginia Sierra-Torre; Santiago Signorelli; Payel Sil; Bruno J de Andrade Silva; Johnatas D Silva; Eduardo Silva-Pavez; Sandrine Silvente-Poirot; Rachel E Simmonds; Anna Katharina Simon; Hans-Uwe Simon; Matias Simons; Anurag Singh; Lalit P Singh; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Sudha B Singh; Sunaina Singh; Surinder Pal Singh; Debasish Sinha; Rohit Anthony Sinha; Sangita Sinha; Agnieszka Sirko; Kapil Sirohi; Efthimios L Sivridis; Panagiotis Skendros; Aleksandra Skirycz; Iva Slaninová; Soraya S Smaili; Andrei Smertenko; Matthew D Smith; Stefaan J Soenen; Eun Jung Sohn; Sophia P M Sok; Giancarlo Solaini; Thierry Soldati; Scott A Soleimanpour; Rosa M Soler; Alexei Solovchenko; Jason A Somarelli; Avinash Sonawane; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Kunhua Song; Zhiyin Song; Leandro R Soria; Maurizio Sorice; Alexander A Soukas; Sandra-Fausia Soukup; Diana Sousa; Nadia Sousa; Paul A Spagnuolo; Stephen A Spector; M M Srinivas Bharath; Daret St Clair; Venturina Stagni; Leopoldo Staiano; Clint A Stalnecker; Metodi V Stankov; Peter B Stathopulos; Katja Stefan; Sven Marcel Stefan; Leonidas Stefanis; Joan S Steffan; Alexander Steinkasserer; Harald Stenmark; Jared Sterneckert; Craig Stevens; Veronika Stoka; Stephan Storch; Björn Stork; Flavie Strappazzon; Anne Marie Strohecker; Dwayne G Stupack; Huanxing Su; Ling-Yan Su; Longxiang Su; Ana M Suarez-Fontes; Carlos S Subauste; Selvakumar Subbian; Paula V Subirada; Ganapasam Sudhandiran; Carolyn M Sue; Xinbing Sui; Corey Summers; Guangchao Sun; Jun Sun; Kang Sun; Meng-Xiang Sun; Qiming Sun; Yi Sun; Zhongjie Sun; Karen K S Sunahara; Eva Sundberg; Katalin Susztak; Peter Sutovsky; Hidekazu Suzuki; Gary Sweeney; J David Symons; Stephen Cho Wing Sze; Nathaniel J Szewczyk; Anna Tabęcka-Łonczynska; Claudio Tabolacci; Frank Tacke; Heinrich Taegtmeyer; Marco Tafani; Mitsuo Tagaya; Haoran Tai; Stephen W G Tait; Yoshinori Takahashi; Szabolcs Takats; Priti Talwar; Chit Tam; Shing Yau Tam; Davide Tampellini; Atsushi Tamura; Chong Teik Tan; Eng-King Tan; Ya-Qin Tan; Masaki Tanaka; Motomasa Tanaka; Daolin Tang; Jingfeng Tang; Tie-Shan Tang; Isei Tanida; Zhipeng Tao; Mohammed Taouis; Lars Tatenhorst; Nektarios Tavernarakis; Allen Taylor; Gregory A Taylor; Joan M Taylor; Elena Tchetina; Andrew R Tee; Irmgard Tegeder; David Teis; Natercia Teixeira; Fatima Teixeira-Clerc; Kumsal A Tekirdag; Tewin Tencomnao; Sandra Tenreiro; Alexei V Tepikin; Pilar S Testillano; Gianluca Tettamanti; Pierre-Louis Tharaux; Kathrin Thedieck; Arvind A Thekkinghat; Stefano Thellung; Josephine W Thinwa; V P Thirumalaikumar; Sufi Mary Thomas; Paul G Thomes; Andrew Thorburn; Lipi Thukral; Thomas Thum; Michael Thumm; Ling Tian; Ales Tichy; Andreas Till; Vincent Timmerman; Vladimir I Titorenko; Sokol V Todi; Krassimira Todorova; Janne M Toivonen; Luana Tomaipitinca; Dhanendra Tomar; Cristina Tomas-Zapico; Sergej Tomić; Benjamin Chun-Kit Tong; Chao Tong; Xin Tong; Sharon A Tooze; Maria L Torgersen; Satoru Torii; Liliana Torres-López; Alicia Torriglia; Christina G Towers; Roberto Towns; Shinya Toyokuni; Vladimir Trajkovic; Donatella Tramontano; Quynh-Giao Tran; Leonardo H Travassos; Charles B Trelford; Shirley Tremel; Ioannis P Trougakos; Betty P Tsao; Mario P Tschan; Hung-Fat Tse; Tak Fu Tse; Hitoshi Tsugawa; Andrey S Tsvetkov; David A Tumbarello; Yasin Tumtas; María J Tuñón; Sandra Turcotte; Boris Turk; Vito Turk; Bradley J Turner; Richard I Tuxworth; Jessica K Tyler; Elena V Tyutereva; Yasuo Uchiyama; Aslihan Ugun-Klusek; Holm H Uhlig; Marzena Ułamek-Kozioł; Ilya V Ulasov; Midori Umekawa; Christian Ungermann; Rei Unno; Sylvie Urbe; Elisabet Uribe-Carretero; Suayib Üstün; Vladimir N Uversky; Thomas Vaccari; Maria I Vaccaro; Björn F Vahsen; Helin Vakifahmetoglu-Norberg; Rut Valdor; Maria J Valente; Ayelén Valko; Richard B Vallee; Angela M Valverde; Greet Van den Berghe; Stijn van der Veen; Luc Van Kaer; Jorg van Loosdregt; Sjoerd J L van Wijk; Wim Vandenberghe; Ilse Vanhorebeek; Marcos A Vannier-Santos; Nicola Vannini; M Cristina Vanrell; Chiara Vantaggiato; Gabriele Varano; Isabel Varela-Nieto; Máté Varga; M Helena Vasconcelos; Somya Vats; Demetrios G Vavvas; Ignacio Vega-Naredo; Silvia Vega-Rubin-de-Celis; Guillermo Velasco; Ariadna P Velázquez; Tibor Vellai; Edo Vellenga; Francesca Velotti; Mireille Verdier; Panayotis Verginis; Isabelle Vergne; Paul Verkade; Manish Verma; Patrik Verstreken; Tim Vervliet; Jörg Vervoorts; Alexandre T Vessoni; Victor M Victor; Michel Vidal; Chiara Vidoni; Otilia V Vieira; Richard D Vierstra; Sonia Viganó; Helena Vihinen; Vinoy Vijayan; Miquel Vila; Marçal Vilar; José M Villalba; Antonio Villalobo; Beatriz Villarejo-Zori; Francesc Villarroya; Joan Villarroya; Olivier Vincent; Cecile Vindis; Christophe Viret; Maria Teresa Viscomi; Dora Visnjic; Ilio Vitale; David J Vocadlo; Olga V Voitsekhovskaja; Cinzia Volonté; Mattia Volta; Marta Vomero; Clarissa Von Haefen; Marc A Vooijs; Wolfgang Voos; Ljubica Vucicevic; Richard Wade-Martins; Satoshi Waguri; Kenrick A Waite; Shuji Wakatsuki; David W Walker; Mark J Walker; Simon A Walker; Jochen Walter; Francisco G Wandosell; Bo Wang; Chao-Yung Wang; Chen Wang; Chenran Wang; Chenwei Wang; Cun-Yu Wang; Dong Wang; Fangyang Wang; Feng Wang; Fengming Wang; Guansong Wang; Han Wang; Hao Wang; Hexiang Wang; Hong-Gang Wang; Jianrong Wang; Jigang Wang; Jiou Wang; Jundong Wang; Kui Wang; Lianrong Wang; Liming Wang; Maggie Haitian Wang; Meiqing Wang; Nanbu Wang; Pengwei Wang; Peipei Wang; Ping Wang; Ping Wang; Qing Jun Wang; Qing Wang; Qing Kenneth Wang; Qiong A Wang; Wen-Tao Wang; Wuyang Wang; Xinnan Wang; Xuejun Wang; Yan Wang; Yanchang Wang; Yanzhuang Wang; Yen-Yun Wang; Yihua Wang; Yipeng Wang; Yu Wang; Yuqi Wang; Zhe Wang; Zhenyu Wang; Zhouguang Wang; Gary Warnes; Verena Warnsmann; Hirotaka Watada; Eizo Watanabe; Maxinne Watchon; Anna Wawrzyńska; Timothy E Weaver; Grzegorz Wegrzyn; Ann M Wehman; Huafeng Wei; Lei Wei; Taotao Wei; Yongjie Wei; Oliver H Weiergräber; Conrad C Weihl; Günther Weindl; Ralf Weiskirchen; Alan Wells; Runxia H Wen; Xin Wen; Antonia Werner; Beatrice Weykopf; Sally P Wheatley; J Lindsay Whitton; Alexander J Whitworth; Katarzyna Wiktorska; Manon E Wildenberg; Tom Wileman; Simon Wilkinson; Dieter Willbold; Brett Williams; Robin S B Williams; Roger L Williams; Peter R Williamson; Richard A Wilson; Beate Winner; Nathaniel J Winsor; Steven S Witkin; Harald Wodrich; Ute Woehlbier; Thomas Wollert; Esther Wong; Jack Ho Wong; Richard W Wong; Vincent Kam Wai Wong; W Wei-Lynn Wong; An-Guo Wu; Chengbiao Wu; Jian Wu; Junfang Wu; Kenneth K Wu; Min Wu; Shan-Ying Wu; Shengzhou Wu; Shu-Yan Wu; Shufang Wu; William K K Wu; Xiaohong Wu; Xiaoqing Wu; Yao-Wen Wu; Yihua Wu; Ramnik J Xavier; Hongguang Xia; Lixin Xia; Zhengyuan Xia; Ge Xiang; Jin Xiang; Mingliang Xiang; Wei Xiang; Bin Xiao; Guozhi Xiao; Hengyi Xiao; Hong-Tao Xiao; Jian Xiao; Lan Xiao; Shi Xiao; Yin Xiao; Baoming Xie; Chuan-Ming Xie; Min Xie; Yuxiang Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Congfeng Xu; En Xu; Haoxing Xu; Jing Xu; JinRong Xu; Liang Xu; Wen Wen Xu; Xiulong Xu; Yu Xue; Sokhna M S Yakhine-Diop; Masamitsu Yamaguchi; Osamu Yamaguchi; Ai Yamamoto; Shunhei Yamashina; Shengmin Yan; Shian-Jang Yan; Zhen Yan; Yasuo Yanagi; Chuanbin Yang; Dun-Sheng Yang; Huan Yang; Huang-Tian Yang; Hui Yang; Jin-Ming Yang; Jing Yang; Jingyu Yang; Ling Yang; Liu Yang; Ming Yang; Pei-Ming Yang; Qian Yang; Seungwon Yang; Shu Yang; Shun-Fa Yang; Wannian Yang; Wei Yuan Yang; Xiaoyong Yang; Xuesong Yang; Yi Yang; Ying Yang; Honghong Yao; Shenggen Yao; Xiaoqiang Yao; Yong-Gang Yao; Yong-Ming Yao; Takahiro Yasui; Meysam Yazdankhah; Paul M Yen; Cong Yi; Xiao-Ming Yin; Yanhai Yin; Zhangyuan Yin; Ziyi Yin; Meidan Ying; Zheng Ying; Calvin K Yip; Stephanie Pei Tung Yiu; Young H Yoo; Kiyotsugu Yoshida; Saori R Yoshii; Tamotsu Yoshimori; Bahman Yousefi; Boxuan Yu; Haiyang Yu; Jun Yu; Jun Yu; Li Yu; Ming-Lung Yu; Seong-Woon Yu; Victor C Yu; W Haung Yu; Zhengping Yu; Zhou Yu; Junying Yuan; Ling-Qing Yuan; Shilin Yuan; Shyng-Shiou F Yuan; Yanggang Yuan; Zengqiang Yuan; Jianbo Yue; Zhenyu Yue; Jeanho Yun; Raymond L Yung; David N Zacks; Gabriele Zaffagnini; Vanessa O Zambelli; Isabella Zanella; Qun S Zang; Sara Zanivan; Silvia Zappavigna; Pilar Zaragoza; Konstantinos S Zarbalis; Amir Zarebkohan; Amira Zarrouk; Scott O Zeitlin; Jialiu Zeng; Ju-Deng Zeng; Eva Žerovnik; Lixuan Zhan; Bin Zhang; Donna D Zhang; Hanlin Zhang; Hong Zhang; Hong Zhang; Honghe Zhang; Huafeng Zhang; Huaye Zhang; Hui Zhang; Hui-Ling Zhang; Jianbin Zhang; Jianhua Zhang; Jing-Pu Zhang; Kalin Y B Zhang; Leshuai W Zhang; Lin Zhang; Lisheng Zhang; Lu Zhang; Luoying Zhang; Menghuan Zhang; Peng Zhang; Sheng Zhang; Wei Zhang; Xiangnan Zhang; Xiao-Wei Zhang; Xiaolei Zhang; Xiaoyan Zhang; Xin Zhang; Xinxin Zhang; Xu Dong Zhang; Yang Zhang; Yanjin Zhang; Yi Zhang; Ying-Dong Zhang; Yingmei Zhang; Yuan-Yuan Zhang; Yuchen Zhang; Zhe Zhang; Zhengguang Zhang; Zhibing Zhang; Zhihai Zhang; Zhiyong Zhang; Zili Zhang; Haobin Zhao; Lei Zhao; Shuang Zhao; Tongbiao Zhao; Xiao-Fan Zhao; Ying Zhao; Yongchao Zhao; Yongliang Zhao; Yuting Zhao; Guoping Zheng; Kai Zheng; Ling Zheng; Shizhong Zheng; Xi-Long Zheng; Yi Zheng; Zu-Guo Zheng; Boris Zhivotovsky; Qing Zhong; Ao Zhou; Ben Zhou; Cefan Zhou; Gang Zhou; Hao Zhou; Hong Zhou; Hongbo Zhou; Jie Zhou; Jing Zhou; Jing Zhou; Jiyong Zhou; Kailiang Zhou; Rongjia Zhou; Xu-Jie Zhou; Yanshuang Zhou; Yinghong Zhou; Yubin Zhou; Zheng-Yu Zhou; Zhou Zhou; Binglin Zhu; Changlian Zhu; Guo-Qing Zhu; Haining Zhu; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Yanping Zhu; Yushan Zhu; Haixia Zhuang; Xiaohong Zhuang; Katarzyna Zientara-Rytter; Christine M Zimmermann; Elena Ziviani; Teresa Zoladek; Wei-Xing Zong; Dmitry B Zorov; Antonio Zorzano; Weiping Zou; Zhen Zou; Zhengzhi Zou; Steven Zuryn; Werner Zwerschke; Beate Brand-Saberi; X Charlie Dong; Chandra Shekar Kenchappa; Zuguo Li; Yong Lin; Shigeru Oshima; Yueguang Rong; Judith C Sluimer; Christina L Stallings; Chun-Kit Tong Journal: Autophagy Date: 2021-02-08 Impact factor: 13.391
Authors: Zhaodong Ji; Yan Shen; Xu Feng; Yue Kong; Yang Shao; Jiao Meng; Xiaofei Zhang; Gong Yang Journal: Front Oncol Date: 2020-10-19 Impact factor: 6.244
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7